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ABSTRACT
TRPM2 is a non-selective cation channel which is permeable to calcium. Although
expression is highest in the brain, the physiological role for TRPM2 in neurons is
unknown. Furthermore, our understanding of the pathways regulating TRPM2 channel
function requires further investigation. In this thesis, we identified that TRPM2 is
required for NMDAR-dependent LTD. No change in NMDAR expression or function
was observed following genetic deletion of TRPM2. Instead, the loss of NMDAR-LTD
in TRPM2 knockout mice results from diminished GSK-3β activation. We next
examined whether age in vitro could facilitate TRPM2 currents. We demonstrate that
diminished glutathione with age results in the loss of basal TRPM2 channel inhibition.
We subsequently demonstrate that TRPM2 currents are enhanced by oligomeric Aβ, a
peptide proposed to initiate the majority of toxic effects observed in Alzheimer’s
disease. Potentiation of TRPM2 may involve Fyn, a tyrosine kinase implicated in
oxidative stress and neurotoxicity. We demonstrate that Fyn is capable of interacting
with and phosphorylating TRPM2. Acute application of Fyn through the patch pipette
potentiates TRPM2 currents, and a Fyn(39-57) mimetic peptide significantly attenuates
currents in cultured hippocampal neurons. These results are the first to establish a role
for TRPM2 in neurons, and also implicate TRPM2 in neurodegenerative disorders such
as Alzheimer’s disease.
KEYWORDS:
TRPM2, calcium, synaptic plasticity, LTD, NMDA, GSK-3β, aging, glutathione, Fyn,
Alzheimer’s disease
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CHAPTER 1

2

1.1

INTRODUCTION

Transient receptor potential melastatin type 2 (TRPM2) is a non-selective cation
channel permeable to calcium (Ca2+), which belongs to the TRP family of ion channels.
TRPM2 mRNA is the most abundant of TRP channels in the Central Nervous System
(CNS) (Fonfria, Murdock et al., 2006). Several studies have demonstrated a clear role
for TRPM2 in cell death in response to oxidative stress in a variety of cell types,
including neurons (Takahashi et al., 2011); however, a physiological role for TRPM2 in
the CNS has not yet been elucidated. TRPM2 was first cloned and characterized in 2001
(Perraud et al., 2001). Although several factors which activate, inhibit, and modulate
TRPM2 have been identified over the past decade, research into the regulation of
TRPM2 and potential implications for normal function and pathology is still in its
infancy. The purpose of this PhD thesis is to investigate the role of TRPM2, and how
this channel is regulated in hippocampal pyramidal neurons.

1.2

TRANSIENT RECEPTOR POTENTIAL MELASTATIN 2 (TRPM2)
The Transient receptor potential (TRP) family of ion channels are non-selective

cation channels. The first TRP gene was originally identified in Drosophila, where TRP
participates in phototransduction (Montell & Rubin, 1989). To date, 28 TRP channels
have been discovered in mammals, which are divided into six subfamilies including the
canonical (C), vanilloid (V), polycystin (P), mucolipin (ML), ankyrin (A), and
melastatin (M) subfamilies (Clapham, 2007; Nilius & Owsianik, 2011).
The first member of the TRPM subfamily to be described, TRPM1, was
originally identified in melanomas, where its expression is negatively correlated with
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tumour cell proliferation and metastasis (Duncan et al., 1998). Since this time, eight
different TRPM family members (TRPM1-TRPM8) have been described in mammals
(Clapham, 2007). TRPM2, previously known as TRPC7 and LTRPC2, is located on
chromosome 21q22.3 in humans (Nagamine et al., 1998). The gene contains 33 exons
over 90kb, and produces a 5876bp full-length transcript which codes for a 1503 amino
acid protein. In addition to the full length form of the protein, several splice variants of
TRPM2 have also been identified. These include: TRPM2-∆N, a variant with deletion
of amino acids 538-557; TRPM2-∆C, a variant with a deletion of amino acids 12921325; TRPM2-∆N∆C, missing both regions 538-557 and 1292-1325; striatum short
form TRPM2 (SSF-TRPM2), a variant identified in the striatum in which the first Nterminal 214 amino acids are deleted; TRPM2-S, a variant in which a stop codon is
introduced at amino acid 995, producing a non-functional protein which is truncated
after the second transmembrane domain (Uemura et al., 2005; Wehage et al., 2002;
Zhang et al., 2003). TRPM2 mRNA assessed by quantitative real-time polymerase
chain reaction (qRT-PCR) demonstrates a near ubiquitous expression in all tissues
examined, with the exception of bone and cartilage. TRPM2 mRNA is most abundant in
the brain (Fonfria, Murdock et al., 2006).
The structure of TRPM2 is proposed to include 6 transmembrane domains, with
a pore-forming re-entry loop between transmembrane domains 5 and 6. The amino and
carboxy terminal regions of the protein are cytoplasmic, and contain regulatory features
for the channel (Figure 1.1). The amino-terminus of TRPM2 contains a TRPM
homology domain, a region of approximately 700 amino acids (aa) which is largely
conserved across all TRPM family members (Kraft & Harteneck, 2005). Additionally,
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an IQ-like motif identified to be involved in Ca2+-Calmodulin binding to the channel
participates in TRPM2 activation (Tong et al., 2006). In the C-terminal portion of
TRPM2, the coiled-coiled motif is predicted to participate in interactions between
TRPM2 proteins and formation of the functional tetrameric form of the channel (Jiang,
2007). Importantly, the C-terminus of TRPM2 also includes a nucleoside diphosphatelinked moiety X-type homology motif (NUDT9-H) which is required for gating of the
channel by adenosine diphosphate ribose (ADPR), an intracellular ligand for TRPM2.
The NUDT9-H region shares 39% sequence homology to NUDT9, a mitochondrial
ADPR hydrolase that converts ADPR to adenosine monophosphate (AMP) and ribose5-phosphate, but demonstrates less than 1% of the enzymatic activity (Perraud et al.,
2001; Shen et al., 2003). The reduction in activity has been attributed to amino acid
substitutions in the NUDT9-H motif at E1405I/F1406L. Indeed, when these residues are
replaced in TRPM2, gating of TRPM2 by ADPR is lost (Kuhn & Luckhoff, 2004).
The TRPM2 channel has a single channel conductance of approximately 6080pS and a linear current-voltage relationship, with a reversal potential of 0mV (Heiner
et al., 2003; Perraud et al., 2001; Sano et al., 2001). These characteristics demonstrate
that the channel is not gated by voltage, and is a non-selective cation channel. The
permeability ratio of Ca2+ to Na+ (PCa:PNa) is approximately 0.7, demonstrating that the
inward current is predominantly carried by Na+ (Kraft et al., 2004; Sano et al., 2001);
however, the long open time of several hundred milliseconds allows for substantial Ca2+
influx into the cell (Kraft et al., 2004; Perraud et al., 2001; Sano et al., 2001).
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FIGURE 1.1 TRPM2 Structure.
TRPM2 is a 1503aa protein, comprised of intracellular amino and carboxy terminal
regions, and six transmembrane segments with a re
re-entry
entry pore forming loop between
segments 5 and 6. The amino
amino-terminus contains a Ca2+-Calmodulin
Calmodulin binding motif
(CaM) which participates in channel activation. The carboxy terminus contains a highly
conserved TRP box (TRP), a coiled
coiled-coiled
coiled region (CCR) which may participate in
tetrameric assembly, and the nucleoside diphosphate
diphosphate-linked
linked moiety X-type
X
homology
motif (NUDT9-H)
H) which binds adenosine diphosphate ribose (ADPR), the intracellular
agonist for TRPM2.
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TRPM2 represents a particularly unique channel in that it is activated in
response to reactive oxygen and nitrogen species (ROS/RNS) (Takahashi et al., 2011).
In a variety of cell types, several groups have demonstrated that TRPM2 activation by
ROS/RNS can elicit a toxic influx of Ca2+ which leads to cell death (Takahashi et al.,
2011). The mechanism for channel activation following exposure to ROS/RNS has been
attributed predominantly to generation of ADPR, a ligand of TRPM2 which was
accurately predicted based on homology of the NUDT9-H domain of TRPM2 to
NUDT9 (Perraud et al., 2001). Oxidative stress may generate ADPR through two
cellular mechanisms. First, ROS/RNS exposure may lead to DNA damage and
activation of polyADPR polymerase (PARP) and polyADPR glycohydrolase (PARG).
These enzymes convert nicotinamide adenine dinucleotide (NAD+) into polyADPR, and
break down polyADPR into monomeric ADPR, which is then capable of activating
TRPM2 channels (Blenn et al., 2011; Fonfria et al., 2004). The second proposed
mechanism of ROS/RNS activation of TRPM2 involves the breakdown of NAD+ into
ADPR by NUDT9 ADPRase activity in the mitochondria. Indeed, when a
mitochondrial targeted form of NUDT9 was expressed in human embryonic kidney-293
(HEK-293) cells stably expressing an inducible flag-tagged human TRPM2 (HEK293TRPM2), activation of TRPM2 in response to H2O2 treatment was significantly
suppressed (Perraud et al., 2005). The half maximal concentration for activation of
TRPM2 by ADPR (EC50) is estimated at 70 - 90µM (Perraud et al., 2001; Sano et al.,
2001). Importantly, intracellular concentrations of ADPR fall within the range for
endogenous TRPM2 activation at 5-80µM (Gasser & Guse, 2005; Heiner et al., 2006).
A variant of TRPM2 (TRPM2-∆C) which is insensitive to ADPR still responds to H2O2
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exposure, raising the possibility that activation of TRPM2 by oxidative stress may also
occur independent of ADPR production (Wehage et al., 2002).
In addition to ADPR, several studies have proposed that NAD+ is capable of
directly activating TRPM2 channels (Hara et al., 2002; Inamura et al., 2003; Sano et al.,
2001); however, this finding has not been consistently reproduced in the literature
(Perraud et al., 2001; Wehage et al., 2002). In comparison to activation of TRPM2 by
ADPR, the time period between NAD+ application and TRPM2 activation is
significantly longer, raising the possibility that NAD+ activates TRPM2 indirectly
following the generation of ADPR (Sano et al., 2001). Similarly, whether Ca2+ is
capable of directly activating TRPM2 channels or whether its actions on TRPM2 simply
enhance response to ADPR is under debate. It is well accepted that intracellular Ca2+
facilitates TRPM2 currents generated by ADPR (Heiner et al., 2006; McHugh et al.,
2003; Olah et al., 2009; Perraud et al., 2001; J. Starkus et al., 2007). The co-operativity
between ADPR and Ca2+ has been attributed to the binding of 4 Ca2+ ions near the pore
entrance of TRPM2, and also through an interaction between a Ca2+/Calmodulin
complex with the IQ-like motif on the N-terminus of TRPM2 (Csanady & Torocsik,
2009; Tong et al., 2006). In support of direct activation of TRPM2 by Ca2+, TRPM2
splice variants which do not respond to ADPR (TRPM2-∆N, TRPM2-∆C, TRPM2∆N∆C, and SSF-TRPM2) are still activated by 10µM Ca2+ (Du, Xie, & Yue, 2009a).
Importantly, intracellular Ca2+ in micro- and nano-domains are estimated to range as
high as 1-100µM (Fakler & Adelman, 2008). Whether Ca2+ reaches this concentration
near TRPM2 and could represent a physiologically relevant gating mechanism remains
to be determined.
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In addition to activation of TRPM2 by the above mechanisms, TRPM2 currents
are augmented by cyclic ADPR (cADPR), nicotinic acid adenine dinucleotide
phosphate (NAADP), arachidonic acid, and temperature. TRPM2 current potentiation
by cADPR and NAADP has been demonstrated by several groups; however, whether
they act as direct agonists, contribute to channel activation by conversion to ADPR, or
co-activate the channel, shifting the concentration response curve of ADPR required for
channel activation, is still unclear (Beck et al., 2006; Kolisek et al., 2005; Lange et al.,
2008; Tao et al., 2011; Toth & Csanady, 2010). Arachidonic acid has also been
demonstrated to facilitate TRPM2 currents, potentially in response to increased release
of intracellular Ca2+ (Hara et al., 2002). Lastly, heat enhances the permeability of
TRPM2 currents, augmenting currents elicited with β-NAD+ or ADPR at physiological
temperatures (Togashi et al., 2006).
In addition to endogenously occurring agonists of TRPM2, an acidic
environment has been shown to inhibit the channel. An extracellular acidic environment
reversibly suppresses TRPM2 currents at a half-maximal inhibitory concentration (IC50)
ranging from pH 4.7 - 6.5, depending on the concentration of Ca2+ used in solutions.
These studies suggest that extracellular pH inhibits TRPM2 channels by binding to
external residues and/or permeation of H+ and subsequent competition for intracellular
Ca2+ binding sites on the channel, resulting in reduced channel conductance (Du, Xie, &
Yue, 2009b; J. G. Starkus, Fleig, & Penner, 2010; W. Yang et al., 2010). Similarly, an
intracellular acidic environment also inhibits TRPM2 currents with an IC50 of pH 6.7 by
inducing channel closure, through an interaction with Asp933 located on the intracellular
side of the channel between transmembrane domains 4 and 5 and/or competing for
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intracellular Ca2+ binding sites (Du, Xie, & Yue, 2009b; J. G. Starkus et al., 2010; W.
Yang et al., 2010).
Preliminary evidence also implicates glutathione (GSH), a naturally occurring
antioxidant, as an endogenous inhibitor of TRPM2 channels. Extracellular GSH inhibits
cell death induced by H2O2 and TNF-α in insulinoma and monocyte cell lines (Hara et
al., 2002). Furthermore, chemical depletion of intracellular GSH induces an increase in
intracellular Ca2+ through TRPM2 channels in glia and dorsal root ganglion sensory
neurons (Lee et al., 2010; Naziroglu et al., 2011). These studies propose that depletion
of GSH activates TRPM2 through a subsequent increase in oxidative stress, but do not
establish a mechanism of inhibition nor do they determine whether or not endogenously
occurring changes in GSH modulate TRPM2 currents.
At present, there are no specific antagonists to TRPM2. The channel is inhibited,
albeit

non-selectively,

by

various

pharmacological

agents,

including

N-(p-

amycinnamoyl) anthranilic acid (N-ACA), econazole, clotrimazole, and flufenamic acid
(Eisfeld & Luckhoff, 2007; Olah et al., 2009). Research elucidating physiological roles
of TRPM2 has been hindered by the lack of a specific antagonist. In order to
specifically assess the role of TRPM2 in various processes, TRPM2 knockout mice
have been generated (Yamamoto et al., 2008). Studies employing a pharmacological
and/or genetic approach to inhibiting TRPM2 currents have increased our understanding
of the pathological and physiological roles of TRPM2.
Cell death in response to oxidative stress is the best characterized role for
TRPM2. Initial evidence using heterologous expression of TRPM2 in HEK cells, and
endogenous expression of TRPM2 in insulinoma and monocyte cell line cells revealed
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that TRPM2 conferred susceptibility to cell death in response to treatment with H2O2
(Hara et al., 2002). A role for TRPM2 in cell death has since been confirmed in a
variety of cell types including neuronal cell populations in response to H2O2, TNFα, and
Aβ peptide (Fonfria et al., 2005; Jia et al., 2011; Kaneko et al., 2006; Takahashi et al.,
2011; Xie, Macdonald, & Jackson, 2010).
In addition to the established role of TRPM2 in oxidative stress-mediated cell
death, physiological roles for TRPM2 are being actively investigated. For example,
TRPM2 has been implicated in insulin secretion from pancreatic β-cells (Inamura et al.,
2003; Togashi et al., 2006; Uchida et al., 2011). A role for TRPM2 in cytokine
production in monocytes/macrophages has also been established. In particular,
activation of TRPM2 leads to the production of cytokines including CXCL8 (previously
known as interleukin-8 [IL-8]), IL-6, IL-10, and TNF-α (Wehrhahn et al., 2010;
Yamamoto et al., 2008). Increased cytokine production through activation of TRPM2
promotes inflammation. Interestingly, TRPM2 also appears to dampen the
inflammatory response through cellular depolarization and subsequent reduction of
ROS production in phagocytes, thereby minimizing excess inflammation (Di et al.,
2011). Lastly, oxidative stress acts on TRPM2 to enhance endothelial cell permeability
by opening interendothelial junctions, although the precise mechanism(s) involved
requires further investigation (Hecquet et al., 2008). Although the highest level of
TRPM2 expression is found in the brain, a physiological role for TRPM2 in neuronal
cells has not yet been identified. Investigation into the physiological role of TRPM2 in
neurons and regulatory pathways in these cells is therefore of critical importance.
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1.3

TRPM2 IN THE CENTRAL NERVOUS SYSTEM
TRPM2 mRNA is most abundant in brain tissue (Fonfria, Murdock et al., 2006).

At present, TRPM2 expression in the CNS has been demonstrated in microglia,
astrocytes, and in neuronal populations in the hippocampus, substantia nigra, striatum,
cortex, and dorsal root ganglion (DRG) sensory neurons in the spinal cord (Fonfria et
al., 2006; Hill et al., 2006; Kaneko et al., 2006; Kraft et al., 2004; Lee et al., 2010; Olah
et al., 2009). The role of TRPM2 in normal physiological functions and its involvement
in CNS disease is gaining increasing attention.
Activation of TRPM2 by oxidative stress and role in cell death implicates
TRPM2 in various neurological disorders. Genetic studies have associated single
nucleotide polymorphisms (SNPs) in TRPM2 to an increased susceptibility for bipolar
disorder (Kostyrko et al., 2006; McQuillin et al., 2006; Xu et al., 2006; Xu et al., 2009).
A single SNP (P1018L) in TRPM2 has also been identified in tissue from Guamanian
amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) subjects (Hermosura
et al., 2008). Whether other neurological disorders are associated with TRPM2
mutations requires further investigation.
Stroke is associated with increased oxidative stress and calcium dysregulation,
which implicates TRPM2 in the neurodegenerative processes following ischemia. In
cultured cortical neurons, cell death following treatment with H2O2 (50µM for 6 hours,
or 1mM for 20 minutes) was greatly attenuated by knockdown of TRPM2, providing
evidence that TRPM2 promotes cell death in neurons in response to oxidative stress
(Kaneko et al., 2006). In a transient middle cerebral artery occlusion (tMCAO) rat
model of ischemia, expression of TRPM2 mRNA is elevated from 1-4 weeks following
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induction of the stroke. This was attributed to transcriptional upregulation of TRPM2 in
microglia in response to oxidative stress and the cytokine IL-1β (Fonfria et al., 2006).
Pharmacological inhibitors and RNA interference with shRNA targeting TRPM2
reduced infarct volume in vivo and decreased neuronal cell death in vitro following
oxygen glucose deprivation (OGD). Interestingly, this protection appears to be specific
to males, suggesting a potential gender difference in contributions of TRPM2 to
ischemic cell death (Jia et al., 2011).
In addition to a potential role in stroke, TRPM2 has also been implicated in
Alzheimer’s disease (AD). Primary striatal cultures exposed to 20µM monomeric βamyloid, the main component of senile plaques in AD, demonstrate an increase in
intracellular calcium and cell death which was partially blocked when cultures were
transfected with a dominant negative splice variant of TRPM2 (Fonfria et al., 2005). Of
note, these experiments were performed in striatal cultures; however, AD presents with
degeneration of the basal forebrain cholinergic neurons, entorhinal cortex,
hippocampus, and cortex (Coyle, Price, & DeLong, 1983; Gomez-Isla et al., 1996) and
therefore the validity of a striatal culture system to model AD is questionable.
Furthermore, 20µM of Aβ which had not been oligomerized was used to induce calcium
influx and cell death; however, it is the oligomeric form of Aβ that has been shown to
induce an influx of intracellular calcium, significantly increase oxidative stress, and be
particularly toxic to neurons (De Felice et al., 2007; Demuro et al., 2005; Lambert et al.,
1998). Although this study implicates TRPM2 in Alzheimer’s pathology, further
research into the role of TRPM2 is required to validate and expand upon this
preliminary study.
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Recent evidence also suggests that TRPM2 may play a role in spinal cord injury
and neuropathic pain. In a rat model of spinal cord injury, intraperitoneal (IP) injection
of clotrimazole conjugated to polyethylene glycol significantly reduced lipid
peroxidation, an indicator of oxidative stress, when administered 5 minutes after spinal
cord compression (Usul et al., 2006). It is unclear whether inhibition or knockdown of
TRPM2 results in higher functional performance compared to untreated controls in a
spinal cord injury model. Additionally, a recent study demonstrated that TRPM2
mRNA is elevated following sciatic nerve injury. When compared with WT littermate
controls, TRPM2 knockout mice show a reduced immune response and attenuation of
the heightened mechanical and thermal pain responses elicited by sciatic nerve injury,
suggesting that TRPM2 plays a role in neuropathic pain (Haraguchi et al., 2012).
Combined, the above data provides genetic, in vitro, and in vivo evidence that
TRPM2 may be a key player in a variety of CNS disorders. Importantly, a role for
TRPM2 in non-pathological processes in the CNS has not yet been elucidated. To
determine potential physiological roles of TRPM2, it is important to consider location
of expression and channel characteristics. For example, the permeability of TRPM2 to
Ca2+ and activation by oxidative stress are defining characteristics of TRPM2. In the
CNS, Ca2+ plays important roles in development, signal transduction, protein
expression, neurotransmitter release, and synaptic plasticity. As mentioned earlier,
TRPM2 is expressed in neuronal populations in the hippocampus, substantia nigra,
striatum, cortex, and DRG sensory neurons (Chung, Freestone, & Lipski, 2011; Fonfria
et al., 2005; Fonfria et al., 2006; Hill et al., 2006; Kaneko et al., 2006; Kraft et al., 2004;
Lee et al., 2010; Naziroglu et al., 2011; Olah et al., 2009; Uemura et al., 2005).
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Expression of TRPM2 in the hippocampus is particularly interesting because this region
of the brain is critically involved in learning and memory, and neurons in this region of
the brain also demonstrate a selective vulnerability to various pathological insults
(Mattson, Guthrie, & Kater, 1989; Wang & Michaelis, 2010). Within the hippocampus,
TRPM2 mRNA is localized to the pyramidal cell layer, and preliminary evidence
demonstrates a predominantly extrasynaptic distribution in cultured hippocampal
neurons (Olah et al., 2009). TRPM2 currents in these cells can be activated by
ROS/RNS exposure, or by calcium influx through voltage-dependent calcium channels
(VDCC) or NMDARs in the presence of intracellular ADPR (Olah et al., 2009).
Therefore, a greater understanding of VDCCs, NMDARs, and synaptic plasticity may
help to establish a potential physiological role for TRPM2 in hippocampal pyramidal
neurons.

1.4

VOLTAGE-DEPENDENT CALCIUM CHANNELS

Voltage-dependent calcium channels (VDCCs) allow for the influx of Ca2+ following
neuronal depolarization. Strong depolarization will activate L-type, N-type, P/Q-type,
and R-type VDCCs, while a more modest depolarization will activate T-type VDCCs
(Benarroch, 2010). VDCC all contain an obligate pore-forming α-subunit which
determines gating properties of the channel. VDCC α subunits include the Cav1, Cav2,
and Cav3 subunits. The Cav1 α subunit is expressed in L-type VDCCs, the Cav2 α
subunit is expressed in N-, P/Q-, and R-type channels, and the Cav3 α subunit is
expressed in T-type channels. The α subunit of most VDCCs are also found in complex
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with a β-, α2δ, and γ- subunits which modulate trafficking and channel gating (Arikkath
& Campbell, 2003; Benarroch, 2010).
Within hippocampal neurons, VDCCs are involved in both pre- and postsynaptic functions (Catterall, 2011). L-type VDCC are expressed predominantly on the
neuronal soma and proximal dendrites where they participate in incorporating synaptic
input and coupling Ca2+ influx to gene transcription (Bading, Ginty, & Greenberg,
1993; Christie et al., 1995; Christie, Schexnayder, & Johnston, 1997; Deisseroth, Heist,
& Tsien, 1998; Hell et al., 1993; Murphy, Worley, & Baraban, 1991; Weisskopf, Bauer,
& LeDoux, 1999). In contrast, N, P/Q-, and R-type channels demonstrate a presynaptic
distribution and are mainly involved in neurotransmitter release (Catterall & Few,
2008). Due to the low threshold of depolarization required for activation of T-type
VDCC and their transient kinetics, T-type VDCC channels are associated with rhythmic
bursting in neurons (Perez-Reyes et al., 1998). Whether TRPM2 channels uniquely
couple to specific VDCC has not yet been investigated.

1.5

GLUTAMATE RECEPTORS
Glutamate is the major excitatory neurotransmitter in the nervous system, and is

also a key mediator of neurotoxicity. Glutamate receptors are classified as either
metabotropic or ionotropic. The metabotropic glutamate receptors (mGluR1-8) couple
to G-proteins to activate downstream signaling cascades. The ionotropic glutamate
receptors are ligand-gated non-selective cation-permeable ion channels, allowing for the
movement of Na+, K+, and sometimes Ca2+. These receptors include the N-methyl-ᴅaspartate (NMDA), α-amino-3-hyroxy-5-methyl-4-isoazoleproprionic acid (AMPA),
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and 2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine (kainate) receptors (Kew &
Kemp, 2005).
AMPA Receptors (AMPARs) in the CNS are tetramers. Subunits are termed
GluR1-4. In the hippocampus, AMPARs are contain GluR2 in combination with GluR1
or GluR3 subunits, with GluR2-GluR1 being the most common at CA3-CA1 synapses
(W. Lu et al., 2009). In the adult CNS, presence of the GluR2 subunit abolishes Ca2+
permeability of AMPA Receptors; therefore, the majority of AMPAR current is
attributed to influx of Na+ and efflux of K+ ions (Geiger et al., 1995; Hollmann, Hartley,
& Heinemann, 1991). Synaptic transmission in the hippocampus is predominantly
mediated through these receptors (Derkach et al., 2007).
NMDARs are comprised of two obligate GluN1 subunits in combination with
two GluN2 subunits (GluN2 A-D) or two GluN3 subunits (GluN3 A or B) (Kew &
Kemp, 2005). Under normal physiological conditions, the release of glutamate during
synaptic transmission results in the activation of AMPARs, depolarizing the postsynaptic cell. This change in voltage relieves the Mg2+ block of NMDA channels,
permitting cation influx following co-activation by glutamate and glycine. This results
in an acute, non-toxic rise in intracellular Ca2+ that is buffered by a variety of
mechanisms (Derkach et al., 2007; Mattson, 2007). In pathological conditions,
excessive Ca2+ entry via NMDARs has been shown to be particularly neurotoxic
(MacDonald, Xiong, & Jackson, 2006; Sattler et al., 1998; Tymianski et al., 1993).
In the adult hippocampus, GluN2A and GluN2B containing NMDARs are the
most abundant. GluN2B-containing NMDAR demonstrate a largely extrasynaptic
distribution, while synaptic NMDARs are comprised predominantly of GluN2A-
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containing NMDARs (Monyer et al., 1994). Interestingly, NMDARs have been
associated with dichotomous signaling toward survival and apoptosis pathways, and
also in synaptic plasticity. Although still a matter of debate, some explanations for the
differences in signaling include synaptic vs. extrasynaptic localization of NMDARs,
stimulus intensity, and subunit specific differences between GluN2B and GluN2A
(Choi, 1985; Dudek & Bear, 1992; Hardingham, Fukunaga, & Bading, 2002;
Ikonomidou et al., 1999; Ikonomidou, Stefovska, & Turski, 2000; L. Liu et al., 2004; Y.
Liu et al., 2007; Mulkey & Malenka, 1992; Sattler et al., 2000).

1.6

SYNAPTIC PLASTICITY
Synaptic plasticity describes the strengthening or weakening of connections

between neurons. These experience-dependent changes are implicated in learning and
memory (Ho, Lee, & Martin, 2011; Malenka & Bear, 2004; Whitlock et al., 2006). A
strong stimulus results in the strengthening of synaptic connections (potentiation),
whereas a weak stimulus will produce a weakening of the synaptic connection
(depression). When these changes are maintained for minutes to hours, the changes are
termed long-term potentiation (LTP) or long-term depression (LTD). Long-term
changes in synaptic strength require the synthesis of new proteins (Greer & Greenberg,
2008; Kandel, 2001). Furthermore, pre-synaptic, trans-synaptic, and post-synaptic
modifications are also involved in the induction and maintenance of experiencedependent synaptic changes (Ho et al., 2011; Malenka & Bear, 2004). Pre-synaptic
mechanisms of synaptic plasticity often alter the likelihood of neurotransmitter release
(Catterall & Few, 2008). At the synaptic cleft, release of trans-synaptic signaling

18

molecules can activate a variety of signaling cascades in the pre-synaptic neuron
(Regehr, Carey, & Best, 2009). Furthermore, LTP and LTD both involve alterations to
adhesion molecules which alter signaling cascades and promote remodeling of the
synapse (Dalva, McClelland, & Kayser, 2007). Post-synaptic changes underlying LTP
and LTD include post-translational modifications and altered protein trafficking (Ho et
al., 2011; Santos et al., 2009).
LTP and LTD require influx of Ca2+ (Cavazzini, Bliss, & Emptage, 2005; Greer
& Greenberg, 2008; Lisman, Schulman, & Cline, 2002; MacDonald, Jackson, &
Beazely, 2006). Importantly, calcium-permeable TRPM2 channels are expressed and
functional in hippocampal pyramidal neurons (Olah et al., 2009); therefore, a greater
understanding of synaptic plasticity at these synapses is required to explore a potential
physiological role for TRPM2.
NMDAR-dependent LTP and LTD is the major form of synaptic plasticity at
hippocampal CA3-CA1 glutamatergic synapses (MacDonald et al., 2006). In the
hippocampus, LTP and LTD are experimentally induced by stimulation of the Schaffer
collateral pathway. This activates axon collaterals of glutamatergic neurons in the CA3
area of the hippocampus which synapse upon CA1 pyramidal neurons. The resulting
excitatory post-synaptic potential (EPSP) can then be recorded by field recordings
extracellular of the CA1 neurons (Figure 1.2). Basal stimulation (~0.1Hz) results in an
EPSP mediated predominantly by AMPAR. When a low-frequency (1Hz) or highfrequency (100Hz) stimulation is applied, NMDAR are also activated, allowing for
influx of Ca2+ and induction of LTD or LTP, respectively (Collingridge, Kehl, &
McLennan, 1983; Collingridge, Herron, & Lester, 1988; MacDonald et al., 2006).
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Activation of NMDAR is required for synaptic plasticity in vitro and in vivo
(Collingridge et al., 1983; Davis, Butcher, & Morris, 1992; Morris et al., 1986).
The bidirectional plasticity induced by activation of NMDARs suggests that the
amount of glutamate released, distribution or subtype of activated NMDARs, and/or the
amount, kinetics, or subcellular location of Ca2+ influx may activate different
downstream pathways and uniquely alter the post-synaptic response to stimulation
(MacDonald et al., 2006). The large increase in intracellular Ca2+ following a high
frequency stimulation activates calcium/calmodulin-dependent protein kinase II
(CaMKII), which phosphorylates AMPARs, increasing conductance of the receptor
(Lisman et al., 2002; Malenka & Bear, 2004). Several other kinases including protein
kinase C (PKC), mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3kinase (PI3K) also participate in phosphorylation of AMPAR, trafficking of AMPAR to
the synapse, and structural modifications to synapses which increase basal synaptic
transmission (W. Lu et al., 2001; Malenka & Bear, 2004). Furthermore, the tyrosine
kinase Fyn is required for induction of LTP, and the tyrosine kinase Src is activated
during LTP and participates in enhancing NMDAR function (Grant et al., 1992; Salter
& Kalia, 2004; K. Yang et al., 2011).
The mechanisms underlying NMDAR-dependent LTD are less well established
(Collingridge et al., 2010). Briefly, a modest increase in Ca2+ during NMDARdependent LTD promotes the Ca2+ dependent activation of calcineurin, also known as
protein phosphatase 2B (PP2B). This leads to activation of protein phosphatase 1 (PP1),
which dephosphorylates AMPAR and decreases receptor conductance. PP1 also dephosphorylates and activates glycogen synthase kinase-3β (GSK-3β), which in turn
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plays a role in the endocytosis of the scaffolding protein post-synaptic density-95 (PSD95). Additionally, Ca2+ activates hippocalcin which targets adaptor protein 2 (AP2) to
the synapse, further increasing AMPAR endocytosis (Collingridge et al., 2010). Fyn
also participates in enhancing LTD through phosphorylation and subsequent
potentiation of GluN2B-containing NMDARs (L. Liu et al., 2004; Nakazawa et al.,
2001; K. Yang et al., 2011).
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Figure 1.2. Hippocampal slice preparation.
Shown above is a transverse section of the hippocampus, used to assess synaptic
plasticity at hippocampal CA3-CA1 synapses. Neurons from the CA3 region of the
hippocampus project axon collaterals to CA1 pyramidal cells; this is known as the
Schaffer collateral pathway. Stimulation of the Schaffer collateral pathway depolarizes
CA3 axons, resulting in glutamate release which acts upon the post-synaptic CA1
neurons. A recording electrode placed extracellular to the CA1 neurons is used to
quantify the resulting field excitatory post-synaptic potential (fEPSP). An increase or
decrease in the fEPSP which is maintained for one hour following various stimulation
protocols is termed long-term potentiation (LTP) or long-term depression (LTD),
respectively. Adapted from Ho et al (2011).
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1.7

AGING AND CALCIUM DYNAMICS
Homeostatic control of intracellular Ca2+ is important to maintain normal

physiological function of neurons, including regulation of synaptic plasticity. Prolonged
or excessive alterations in Ca2+ concentrations can lead to cytotoxicity (Choi, 1985;
Dirnagl, Iadecola, & Moskowitz, 1999; Orrenius, Zhivotovsky, & Nicotera, 2003). A
sudden and excessive increase in intracellular calcium triggers necrotic death in
neurons, while milder but sustained elevations in calcium promotes delayed cell death
through a combination of apoptotic and necrotic pathways. We previously reviewed the
variety of pathways through which Ca2+ levels are altered following ischemia (Belrose
et al., 2012). In addition to a dysregulation of Ca2+ in pathology, control of Ca2+ levels
can also be compromised during normal aging in response to energy impairment and
increased oxidative stress (Figure 1.3) (Mattson, 2007).
The primary theory underlying the increase in oxidative stress with age was
described in 1972 and termed the “mitochondrial free radical theory of aging” (Harman,
1972). Mitochondria are the site of ATP production in the cell, and use the majority of
the cell’s oxygen for the oxidative phosphorylation process. ROS are a byproduct of this
process. Oxidative stress in the aging brain leads to lipid peroxidation, DNA damage,
modifications to ligand and voltage gated Ca2+ channels, and endoplasmic reticulum
(ER) dysfunction promoting aberrant release of Ca2+ from internal stores (Mattson,
1998; Mattson, 2007). Furthermore, oxidative stress contributes to mitochondrial
dysfunction, resulting in diminished ATP levels, and impairing ion-motive ATPases
which participate in regulating intracellular Ca2+ levels (Mattson, 2007; Mattson, 2007;
Navarro & Boveris, 2007). This creates a positive feedback loop whereby ROS
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produced by the mitochondria contribute to cellular dysfunction and reduce efficiency
of the mitochondria, ultimately resulting in enhanced ROS production. The energy
impairment and oxidative stress converge on multiple pathways to promote
dysregulation of neuronal Ca2+ levels during normal aging.
The consequence of elevated intracellular Ca2+ includes changes in synaptic
plasticity and cell viability. Interestingly, although NMDAR-dependent LTP is impaired
with age, the total magnitude of LTP is largely preserved during normal aging,
potentially through a compensatory upregulation in VDCC-dependent LTP (Robillard et
al., 2011). LTD, in contrast, is enhanced with normal aging (Norris, Korol, & Foster,
1996). Combined, these changes in synaptic plasticity produce an age-dependent
decrease in synaptic strength which may underlie memory impairment with normal
aging. Furthermore, normal aging also results in a reduction in brain volume in several
regions of the brain, including the hippocampus (Long et al., 2012; Scahill et al., 2003;
Sowell et al., 2003). An increase in intracellular Ca2+ levels may underlie the agedependent changes in neuronal structure, function, and viability that contribute to the
observed reduction in brain volume, and altered synaptic plasticity (Foster, 2007; Gant
et al., 2006; Mattson, 2007; Ouanounou et al., 1999; Villalba et al., 1995). The
pathway(s) leading to increased intracellular Ca2+ with age is therefore of critical
importance to our understanding of the age-dependent decrease in synaptic strength and
increase in susceptibility to neurodegeneration.
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Figure 1.3. Aging and Calcium Dynamics.
In the brain, normal aging results in a decrease in ATP production resulting in energy
impairment, and an increase in oxidative stress. These converge to increase intracellular
Ca2+ concentrations in response to chan
changes
ges to several pathways/channels which
participate in Ca2+ homeostasis including voltage
voltage-dependent
dependent calcium channels,
NMDARs, intracellular calcium stores, and ion motive ATP
ATP-ases.
ases. The increase in
intracellular Ca2+ promotes the decreased synaptic strength and increased susceptibility
to cell death observed with age.
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1.8

GLUTATHIONE
Endogenous mechanisms to protect against ROS mediated damage include the

endogenously occurring antioxidants superoxide dismutase (SOD), superoxide
reductase, catalase, and glutathione. These antioxidants may participate in the agedependent increase in Ca2+ influx through their modulation of the oxidative stress status
of the cell. Interestingly, the concentration of glutathione (GSH) decreases with age in
vitro and in vivo, and therefore represents an interesting potential player in the Ca2+
dysregulation observed with age (Chen, Richie, & Lang, 1989; R. M. Liu, 2002;
Parihar, Kunz, & Brewer, 2008; Rebrin, Forster, & Sohal, 2007; Sasaki et al., 2001).
GSH is a tripeptide of glutamate, cysteine, and glycine. It is synthesized by the
enzymes γ-glutamylcysteine followed by glutathione synthases. Both of these steps
require ATP. The rate limiting step in GSH synthesis is carried out by γglutamylcysteine, due to the limited availability of the cysteine substrate. The
intracellular concentration of GSH typically ranges from 0.2 - 10mM (Anderson, 1998).
In the brain, evidence from cultured cells suggests that GSH levels are higher in glial
cells than in neurons (Dringen & Hamprecht, 1998; Hirrlinger et al., 2002; Raps et al.,
1989). It is less clear whether this is also true in vivo (Miller et al., 2009).
In the CNS, the primary role of GSH is to decrease oxidative damage by
reacting with the ROS/RNS superoxide, nitric oxide, hydroxyl radical, and peroxynitrite
(Clancy et al., 1994; Koppal et al., 1999; Nauser, Koppenol, & Gebicki, 2005;
Winterbourn & Metodiewa, 1994). The cysteine residue in GSH is also important in
minimizing protein oxidation. GSH is capable of forming protein adducts through a
process known as S-glutathionylation to prevent irreversible disulphide bonds between
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oxidized proteins (Dalle-Donne et al., 2007). The depletion of GSH with age not only
increases the oxidative stress status of the cell, but may also be associated with
increased intracellular calcium and subsequent toxicity (Aoyama et al., 2006; Bains &
Shaw, 1997; Gabby et al., 1996; Jurma, Hom, & Andersen, 1997; Thanislass,
Raveendran, & Devaraj, 1995).

1.9

FYN KINASE

A version of this section has been published:
Yang, K.*, Belrose, J.*, Trepanier, C.H., Lei, G., Jackson, M.F., & MacDonald, J.F.
(2011). Fyn, a potential target for Alzheimer’s disease. REVIEW. Journal of
Alzheimer’s Disease, 27(2): 243-252. *these authors contributed equally to this work
The Fyn gene is located at chromosome 6q21. Isoform 1 is a 59kDa protein that
has the most ubiquitous expression pattern among the three identified Fyn isoforms and
is highly expressed in the brain (Cooke & Perlmutter, 1989; Goldsmith, Hall, &
Atkinson, 2002). Homology modeling revealed that the structure is similar to that of
other Src family kinases (SFKs) such as Src. The structure includes the regulatory
domain at the C terminus, the catalytic domain (SH1) domain, the linker region, the Src
homology 2 (SH2) domain, the Src homology 3 (SH3) domain, the unique domain, and
the Src homology 4 (SH4) domain at the N terminus (Ingley, 2008; Roskoski, 2005;
Salter & Kalia, 2004; Thomas & Brugge, 1997; Vatish et al., 2009).
The role of each structural domain has been investigated in Fyn and other SFK
family members. The SH4 domain of Fyn is a very short motif, containing the signals
for lipid modification such as myristoylation and palmitoylation that are responsible for
membrane targeting (Resh, 1993). The importance of this domain was illustrated by
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observations that the specificity of Fyn in cell signaling depended on its subcellular
locations (Sicheri & Kuriyan, 1997). This region is followed by the unique N-terminal
domain, a region of low relative homology to other Src family members (Jelic et al.,
2007). The role of the unique domain remains relatively unexplored; however, it may
serve as a site for selective interactions with proteins that are specific for each family
member (Salter & Kalia, 2004). The Fyn SH3 domain is a 60 amino acid sequence that
interacts with proline rich motifs in a number of signaling molecules and mediates
various protein-protein interactions. The SH2 domain binds to phosphorylated tyrosine
residues of interacting proteins (Ingley, 2008; Roskoski, 2005; Salter & Kalia, 2004;
Thomas & Brugge, 1997; Vatish et al., 2009). The catalytic SH1 domain is highly
conserved among SFKs. It includes an ATP binding site which is required for the
phosphoryation of Fyn substrates. The SFK inhibitor PP2 binds to this site, inhibiting
the phosphorylation of Fyn substrates (Osterhout et al., 1999).
As with other SFK members, the catalytic function of Fyn is tightly regulated by
phosphorylation. Foremost, phosphorylation of Y420, located in the activation loop of
the SH1 domain, is necessary for Fyn activation (Cheng et al., 1991). The degree of Fyn
activation is often measured by the level of phosphorylated Y420 normalized to total Fyn
expression. In addition to Y420, phosphorylation of S21 is also involved in the regulation
of Fyn. Mutation of this site blocked protein kinase A (PKA) phosphorylation of Fyn
and diminished kinase activity (Yeo et al., 2011). Basal Fyn activity is low due to
intramolecular interactions between the SH2 domain and phosphorylated Y531 in the Cterminus and/or between the SH3 domain and the linker region of Fyn. Phosphorylation
of Fyn at Y531 leads to an inhibition of Fyn activity (Relucio et al., 2009). When this site
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is dephosphorylated by phosphatases including protein tyrosine phosphatase α (PTPα)
and Src homology-2-domain-containing phosphatase (SHP1/2), Fyn activity is
enhanced (Samayawardhena & Pallen, 2010; X. Yang, Dutta, & Shaw, 2010).
Fyn is an important player in synaptic plasticity. As mentioned previously, Fyn
is required for induction of LTP at the CA3/CA1 synapse. The requirement for Fyn in
LTP induction is unique amongst the Src family kinases since knockout of Src -/-, Yes /-, and Abl -/- mice show no change in LTP (Grant et al., 1992; Kojima et al., 1997).
The requirement for Fyn in synaptic plasticity is, at least in part, attributed to regulation
of NMDA and AMPA Receptors. Potential sites of Fyn phosphorylation on the GluN2B
subunit of NMDARs include Y1252, Y1336, and Y1472 (Nakazawa et al., 2001).
Phosphorylation of GluN2B at Y1472 by Fyn enhances GluN2B-NMDAR currents, and
facilitates LTD (K. Yang et al., 2011). Phosphorylation at these sites may also
differentially alter NMDAR activity by enhancing degradation of the NMDAR,
promoting truncation of GluN2 subunits, or by increasing insertion of NMDARs to the
plasma membrane (Hu et al., 2010; Jurd et al., 2008; Lau & Zukin, 2007; Rong et al.,
2001; Wu et al., 2007). Interestingly, it appears that scaffolding proteins such as post
synaptic density 93 (PSD-93) or PSD-95 might promote the phosphorylation of
NMDARs by Fyn (Sato et al., 2008; Tezuka et al., 1999). Furthermore, Fyn
phosphorylation of GluN2A and GluN2B facilitates the binding of NMDARs to PSD95, an interaction that has been linked to toxicity in stroke and in Alzheimer’s disease
(Aarts et al., 2002; Ittner et al., 2010; Rong et al., 2001).
Regulation of AMPARs is a crucial mechanism in synaptic plasticity (Santos et
al., 2009). In neocortical neurons, both BDNF and platelet derived growth factor
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(PDGF) enhanced surface expression of AMPARs via Fyn. The increase of AMPAR
was blocked by a PTK inhibitor and was also absent in Fyn -/-mice (Narisawa-Saito et
al., 1999). Transgenic mice overexpressing either wild type Fyn or constitutively
activated Fyn have also been generated. Mice overexpressing constitutively active Fyn
demonstrate enhanced basal synaptic transmission, and facilitated LTP using a weak
theta-burst stimulation protocol. In contrast, the basal synaptic transmission and the
threshold for the induction of LTP were not altered in the slices overexpressing wild
type Fyn (Y. F. Lu et al., 1999). The regulation of NMDARs, AMPARs, and LTP
induction outlined here demonstrate that Fyn plays a role in synaptic plasticity.
Importantly, Fyn kinase also plays a role in pathological conditions. For
example, ROS increases autophosphorylation of Fyn in fibroblasts, and upregulates
expression of Fyn in a model of chronic myelogenous leukemia (Gao et al., 2009;
Sanguinetti, Cao, & Corley Mastick, 2003). Whether TRPM2 is also a target of Fyn
kinase has not yet been explored; however, a recent paper has demonstrated that
TRPM2 is tyrosine phosphorylated following exposure to oxidative stress. Inhibition of
Src family kinases with PP2 decreases TRPM2 mediated Ca2+ influx in response to
H2O2 treatment (Zhang et al., 2007). Combined, this data implicates Fyn in the
regulation of TRPM2 channels.
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1.10

HYPOTHESIS AND OBJECTIVES
TRPM2 is a Ca2+ permeable non-selective ion channel which is activated by

oxidative stress and participates in cell death in a wide variety of cell types (Takahashi
et al., 2011). TRPM2 exhibits the highest level of expression in the brain, where it is
expressed in a variety of cell types including hippocampal pyramidal neurons (Fonfria,
Murdock et al., 2006; Olah et al., 2009). The physiological role for TRPM2 in these
cells, and mechanisms which regulate TRPM2 channels, requires investigation.
Preliminary evidence suggests that TRPM2 may be predominantly localized
extrasynaptically on these neurons (Olah et al., 2009). Interestingly, some studies report
that synaptic localization of NMDARs is more closely associated with LTP, while
extrasynaptically localized NMDARs are more closely associated with LTD (W. Lu et
al., 2001). Furthermore, substantial evidence supports a role for TRPM2 in cell death
(Takahashi et al., 2011), and activation of extrasynaptic localization of NMDAR is
associated with neurotoxicity (Hardingham et al., 2002; Sattler et al., 2000). Therefore,
we hypothesized that TRPM2 participates in NMDAR-dependent LTD at
hippocampal CA3-CA1 synapses.
TRPM2 may also represent a potential mediator of age-dependent Ca2+
dysregulation. First, TRPM2 is activated by oxidative stress. Second, it is permeable to
Ca2+, and TRPM2-mediated calcium-influx leads to cell death in a variety of cell types.
Third, it is expressed in hippocampal pyramidal neurons which are not only critical for
learning and memory, but are also particularly susceptible to cell death during ischemia
and age-dependent neurodegenerative diseases such as Alzheimer’s disease. Therefore,
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we hypothesized that the expression or activity of TRPM2 is increased with age in
vitro in cultured hippocampal pyramidal neurons.
Lastly, TRPM2 is implicated in neuronal cell death in response to oxidative
stress and Aβ (Fonfria et al., 2005; Kaneko et al., 2006). Whether knockout of TRPM2
protects against Aβ oligomer-mediated toxicity has not yet been investigated. We
hypothesized that genetic deletion of TRPM2 will attenuate Aβ oligomer-induced
reduction in cell viability in cultured hippocampal neurons. Pathways which
regulate TRPM2 during oxidative stress and/or following exposure to Aβ have not yet
been elucidated. One potential mediator may be the non-receptor tyrosine kinase, Fyn.
Oxidative stress induces tyrosine phosphorylation of TRPM2 (Zhang et al., 2007). Fyn
kinase SH3 domain participates in protein-protein interactions between Fyn and several
of its substrates via interactions with proline rich (PxxP) motifs in other proteins.
Importantly, TRPM2 contains several proline rich motifs (PxxP) in the N- and Cterminal portions of TRPM2. We hypothesized that Fyn kinase phosphorylates and
interacts with TRPM2, and augments TRPM2 currents.
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2. DEPENDENCE OF NMDA/GSK-3β MEDIATED METAPLASTICITY ON
TRPM2 CHANNELS AT HIPPOCAMPAL CA3-CA1 SYNAPSES

2.1 Introduction
The transient receptor potential melastatin 2 channel (TRPM2) is a novel nonselective cation channel that was initially cloned from the brain, and was subsequently
identified as an effector of calcium fluxes following oxidative stress (Takahashi et al.,
2011). Functionally, TRPM2 has been linked to cell death, cytokine production, and
insulin secretion (Takahashi et al., 2011). Interestingly, TRPM2 expression is greatest
in the central nervous system (CNS) where it may contribute to neurodegenerative
disease (Takahashi et al., 2011; Xie et al., 2011). We recently demonstrated functional
expression of TRPM2 in CA1 pyramidal neurons (Olah et al., 2009), in culture and in
situ. TRPM2 is unique among known ion channels in that it contains a cryptic Cterminal enzyme domain homologous to the NUDT9 ADP-ribose (ADPR) hydrolase.
This channel motif serves primarily as the ligand binding domain for ADPR, which is
required for Ca2+-dependent gating of the channel (Scharenberg, 2005). In hippocampal
neurons, TRPM2 currents can be activated by voltage-ramps that generate inward Ca2+
currents or by strong stimulation of NMDA receptors (NMDARs) (Olah et al., 2009).
Indeed, high concentrations of ADPR are unable to evoke these currents until activated
by an influx of Ca2+. The coupling of channel activity to Ca2+ signaling downstream of
voltage-gated Ca2+ channels and NMDARs suggests that TRPM2 could play a role in
neuronal signaling or synaptic transmission. Given the lack of selective antagonists, we
have examined the hypothesis that these channels contribute to synaptic plasticity by
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employing TRPM2 deficient mice (Yamamoto et al., 2008).

2.1 Methods
Experimental animals
TRPM2 knockout (KO) mice, generated as described previously(Yamamoto et
al., 2008), were provided by Dr Y Mori. Wild-type (WT) and KO mice used for
experimentation were derived from heterozygous matings and mouse genotyping was
performed as previously described (Yamamoto et al., 2008). Mice were kept in a
pathogen-free environment, and analyses were performed using mice that were matched
for age. All animal experiments were performed in accordance with protocols approved
by the University of Western Ontario Animal Use Subcommittee of the University
Council on Animal Care.
Whole-cell recording from primary culture
Mouse hippocampal primary neuronal cultures were prepared from E17-19
embryos using homozygously bred time pregnant TRPM2 KO mice or WT mice
according to previously described procedures (MacDonald et al., 1989). Currents were
recorded at 21-28 days in vitro. Whole-cell voltage-clamp recordings were performed as
described previously (Olah et al., 2009), with minor adjustments. Briefly, standard
intracellular solution (ICS) contained (in mM): 150 cesium gluconate, 10 Hepes, and 2
MgCl2. To record NMDA currents, 11 mM EGTA, 1 mM CaCl2, and 2 mM K2-ATP
was added to the ICS. TRPM2 currents were recorded with 1 mM ADPR added to the
ICS. Standard extracellular solution (ECS) contained (in mM): 140 NaCl, 5.4 KCl, 25
Hepes, 33 glucose, 2 CaCl2, and 0.2 µM TTX. To generate NMDA currents, 50 µM
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NMDA and 0.5 µM glycine was added to the standard ECS and applied for 3 seconds
every minute using a multibarrelled rapid perfusion system (SF77B; Warner
Instruments). For experiments examining the contribution of GluN2B receptor, 1 µM
Ro 25-6981 (Tocris) was applied after having obtained 3 stable control sweeps in its
absence. ADPR-primed TRPM2 currents were generated with voltage ramps ( ± 100
mV over 500ms, applied every 10 sec) in the presence of standard ECS supplemented
with 1 mM MgCl2 and 1 mM BaCl2. After the TRPM2 current stabilized, or after 10
minutes of voltage ramps, calcium-free solution was applied (total divalent concentration maintained by replacing CaCl2 with equimolar BaCl2). Voltage-clamp recordings
(Vhold = -60 mV) were performed at room temperature (20-22°C) using a Multiclamp
700A amplifier (Molecular Devices). Data were filtered at 2 kHz, digitized, and
acquired using pCLAMP and Axoscope software (Molecular Devices).
Hippocampal slices preparation
-/-

Hippocampal slices were prepared from age-matched TRPM2 and wild type
mice (post-natal day 20-30). Briefly, mice were decapitated after isoflurane anesthesia,
and brains were quickly removed and placed in ice-cold oxygenated (95% O2,5%CO2)
artificial CSF (ACSF) containing: 124 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 1.3
mM MgCl2, 2.6 mM CaCl2, 26 mM NaHCO3 and 10 mM glucose (osmolality between
300 and 310 mOsm). Whole-brain coronal slices (300 µm) containing transverse
sections of the hippocampus were prepared using a vibrating microtome (VT100E;
Leica). After a recovery period of 1 h in oxygenated ACSF, hippocampal slices were
transferred to a recording chamber continuously perfused with oxygenated ACSF (3 ml/
min), warmed to 31°C through an in-line solution heater.
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Field excitatory postsynaptic potentials (fEPSP) recording from Schaffer
collateral-CA1 synapses. fEPSPs were evoked every 30 s (0.033 Hz) by electrical
stimulation (100 µs duration) delivered to the Schaffercollateral pathway using a
concentric bipolar stimulating electrode (25 µm exposed tip) and recorded using glass
microelectrodes (3-5 MΩ, filled with ACSF) positioned in the stratum radiatum of the
CA1 area. The stimuli intensity was adjusted to evoke fEPSPs corresponding to
30~50% of the maximal response evoked in the absence of a contaminating spike
discharge. The paired-pulse ratio was determined in each slice by delivering pairs of
stimuli at varying interstimulus intervals (10-1000 ms). For LTD/LTP experiments,
baseline fEPSPs were monitored for at least 20 min to ensure stability, following
which synaptic plasticity was induced by repetitive stimulation at the Schaffer
collaterals delivered at 1, 10, 20, 50 Hz (900 pulses at each frequency) or 100 Hz (four
1 sec trains delivered 20 sec apart). Following repetitive stimulation, fEPSP slopes
were monitored for 1 h. Signals were amplified (Axoclamp 700B, Molecular Devices),
recorded digitally (Digidata 1440A) and analyzed offline using Clampfit 10.
Whole-cell patch clamp recordings from hippocampal slices
Visual patch recordings from CA1 pyramidal neurons were performed using the
whole-cell configuration with holding potential at -60 mV. Patch pipettes, pulled from
borosilicate glass (4-6 MΩ), were filled with an internal solution containing (in mM):
Cs-gluconate 132.5, CsCl 17.5, HEPES 10, EGTA 0.2, Mg-ATP 2 and GTP 0.3 (pH
7.25, 290 mOsm). Synaptic responses were evoked with a concentric bipolar tungsten
electrode located about 50 µm from the cell body layer in CA1. In some recordings,
NMDAR-mediated EPSCs were pharmacologically isolated by supplementing our
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aCSF with CNQX (10 µM). The AMPAR-and NMDAR-mediated EPSCs were
measured at -70 mV and +40 mV, respectively. For NMDAR-EPSCs, the amplitude
was measured 20 ms after the start of the stimulus artifact (von Engelhardt et al., 2010).
Signals were amplified using multiclamp 700B, sampled at 5 kHz, and analyzed with
Clampfit 10 software (Molecular Devices).
Western Blotting
For the basal protein expression and protein phosphorylation assays,
hippocampal tissue from wild type and TRPM2 KO mice (post-natal day 20-30) was
used for Western blot. For experiments involving quinpirole treatment, hippocampal
slices were incubated in ECS solution bubbled with 95%O2 and 5%CO2 at room
temperature for at least 1 h, followed by exposing to quinpirole (10 µM) or vehicle for
30 min in aCSF. After 3 times wash with cold PBS, hippocampal tissue was
homogenized in ice-cold RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM
EDTA, 0.1% SDS, 0.5% Triton-X100, and 1% Sodium Deoxycholate) containing
protease and phosphatase inhibitors. These samples were subjected to SDS-PAGE,
transferred to a nitrocellulose membrane, which was subjected to repeated probing and
stripping with antibodies as described. The signals were quantified using VersaDoc
Imaging System (BioRad). The antibodies PSD-95, pGSK-3βSer9, GSK-3β, GluN2A and
GluN2B were purchased from Cell Signaling Technology, and GluR1 and GluR2 from
Santa Cruz Biotechnology, Inc.

Statistics
Data are expressed as mean ± SEM. Statistical comparisons were made using
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either unpaired t-test or one-way ANOVA followed by Bonferroni post-hoc test,
depending on the experimental protocol.
2.3 Results
Hippocampal neurons were cultured from wildtype (WT) and knockout (KO)
mice using standard procedures outlined in the methods. This allowed us to compare the
activation of TRPM2 currents in cultured pyramidal neurons from both genotypes.
Whole-cell voltage clamp recordings were performed with 1 mM ADPR in the patch
solution. Under these recording conditions TRPM2 currents were absent until multiple
voltage-ramps are used to evoke these slowly developing currents (Figure 2.1). Large
TRPM2 inward currents were generated at a holding potential of -60 mV in neurons
from WT mice (Figure 2.1a, c; 553.4 ± 132 pA, n = 5) but were entirely absent in those
from KO mice (Figure 2.1b; 7.9±7.2pA, n=6; unpaired t-test, p=0.001). Importantly, no
genotypic difference in peak Ca2+ currents were detected (3648 ± 715 pA in WT, 2836
± 390 pA in KO; unpaired t-test, p=0.3234; Figure 2.1d). Furthermore, there were no
changes in peak responses (or steady-state to peak ratios) to applications of NMDA
(Figure 2.1e, f) or in the GluN2B mediated component of this response determined by
application of 1 µM Ro-256981, a highly selective antagonist of GluN2B containing
receptors (Figure 2.1g). These results confirm the functional identification of TRPM2
currents in hippocampal pyramidal neurons, the absence of TRPM2 currents in neurons
cultured from TRPM2 deficient mice, and that the absence of TRPM2 does not alter
either voltage-dependent or NMDAR-dependent Ca2+ currents.
Next, acute transverse hippocampal slices were prepared from TRPM2 KO and
WT mice at 3-4 weeks of age using standard approaches described in the methods. Field
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excitatory postsynaptic potentials (fEPSPs) were recorded from CA3-CA1. We noted
no difference in the paired-pulse ratios between WT and KO mice (Figure 2.2a). We
then examined the effects of a short period of oxygen-glucose deprivation (OGD) on
fEPSPs in slices from both genotypes. In WT slices, OGD resulted in a strong
depression of the fEPSPs. This depression was greatly diminished in TRPM2 KO slices,
consistent with a phenotype of a reduced responsiveness to the oxidative stress
mediated by TRPM2 channels (Figure 2.2b).
TRPM2 currents can be activated by NMDAR stimulation; therefore, we
examined whether TRPM2 might contribute to NMDAR-dependent synaptic plasticity.
We first examined the induction of long-term potentiation (LTP) using a standard 100
-/-

Hz stimulation. No difference in LTP was observed in slices from TRPM2 mice
(Figure 2.3a) suggesting that TRPM2 plays little or no role in this form of synaptic
plasticity. However, NMDARs are also required for one form of long-term depression
(LTD) at these synapses so we extended our studies to include low frequency
stimulation. Applying 900 pulses at 1 Hz induced LTD in WT mice (0.84 ± 0.021, n
=10) but failed to do so in TRPM2 KO mice (Figure 2.3b; 0.98 ± 0.025, n = 10; p =
0.017). Acute applications of the TRPM2 blocker clotrimazole also blocked LTD
induced using this protocol (Figure 2.3c). Clotrimazole did not inhibit the induction of
LTP (data not shown).
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Figure 2.1. NMDAR and Ca2+ current function is preserved in TRPM2 KO
cultured hippocampal neurons.
(a,b) ADPR-primed TRPM2 currents are facilitated by voltage ramps ( ± 100 mV, 1/10
sec) in WT (a), but not in cultured neurons from TRPM2-/- mice (b); (c) Summary bar
graph of ADPR-primed peak current amplitude in WT and TRPM2-/- neurons.
(unpaired t-test p = 0.001, 553.4 ± 132 pA in WT, n = 5; 7.9 ± 7.2 pA in KO, n = 6);
(d) Peak Ca2+ currents elicited by the voltage ramp protocol are not altered by
disruption of TRPM2 channel expression; Neither NMDAR peak currents (e), nor
NMDAR steady state to peak ratios (f) generated in response to rapid applications of
NMDA to cultured hippocampal neurons are affected by loss of TRPM2 expression; (g)
Representative traces and summary bar graph of GluN2B subtype NMDAR inhibition
with Ro 25-6981. Results demonstrate that the contribution of GluN2B subtype
receptors to total NMDAR charge transfer is unaltered in cultured TRPM2 KO
hippocampal neurons relative to control.
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Figure 2.2 OGD-mediated LTD is impaired in the absence of TRPM2
(a) The response to a paired-pulse protocol is identical in hippocampal slices derived
from TRPM2 KO mice and WT controls (n=11 per group), demonstrating that presynaptic short-term plasticity is unaltered in the absence of TRPM2; (b) Transient
oxygen-glucose deprivation (5 min OGD) causes long-lasting depression of fEPSP
slopes in slices from WT (n = 12) but not TRPM2-/- (n = 6).
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LTD at these synapses can also depend upon activation of group 1 mGluRs
rather than NMDARs (Collingridge et al., 2010), we therefore examined responses to a
bath exposure to NMDA (10 µM, 5 min) or DHPG (10 µM, 20 min) in slices of both
genotypes. The LTD induced by DHPG was similar in WT and TRPM2 KO mice
(Figure 2.3d; 0.85 ± 0.043, n = 6 in WT vs 0.80 ± 0.031, n = 7 in TRPM2 KO mice,
respectively; p > 0.05). Conversely, NMDA application induced LTD in slices from
WT (n = 6) but failed to do so in TRPM2 KO mice (Figure 2.3e; n = 6). When plasticity
induced by a range of repetitive stimulation frequencies was examined it was clear that
TRPM2 KO slices demonstrated a substantial impairment in NMDA-dependent LTD
(Figure 2.3f).
The expression of NMDAR-dependent LTD at CA3-CA1 synapses requires the
endocytosis of AMPA Receptors (AMPARs) (Collingridge et al., 2010; Sanderson,
Collingridge, & Fitzjohn, 2011). To determine if there was a change in the functional
expression of AMPARs in TRPM2 KO mice we used whole cell voltage clamp
recordings to measure the ratio of AMPAR to NMDAR mediated EPSCs. By holding
the membrane potential at -70 and +40 mV the relative contribution of each receptor
type was determined. This ratio was significantly reduced in TRPM2 KO (n = 10)
neurons compared to WT (n = 10, p < 0.01; Figure 2.4a). These results suggest that a
reduction of synaptic AMPARs or alternatively an enhancement of NMDARs may
underlie the deficiency of LTD in TRPM2 KO mice. A change in AMPARs was
supported by our observation of a reduction of mEPSC amplitude but not frequency in
TRPM2 KO mice (Figure 2.4b,c,d).
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Figure 2.3 LTD is impaired in hippocampal slices derived from TRPM2 KO mice.
(a) LTP is unaffected by knockout of TRPM2 (WT, n = 6; TRPM2-/-, n = 8); (b) LTD
of fEPSPs evoked by repetitive stimulation (900 stimuli at 1 Hz) in WT slices (n = 10)
is absent in slices from TRPM2 KO mice (n = 10); (c) LTD of fEPSPs was inhibited by
application of clotrimazole, a TRPM2 inhibitor. Timing of clotrimazole application in
treated slices is indicated by the black bar. (d) Metabotropic-glutamate receptor
dependent LTD is unimpaired by deletion of TRPM2 (WT, n = 6; TRPM2 KO, n = 7);
(e) Chem-LTD, evoked by 5 min application of NMDA (10 µM) is abolished in slices
from TRPM2 KO (n = 6) but not WT (n = 6) slices; (f) Summary graph for a series of
recordings from WT and TRPM2 KO slices in which plasticity was induced by
repetitive stimulation delivered at 1, 10, 20, 50 Hz (900 pulses at each frequency) or
100 Hz (four 1 sec trains delivered 20 sec apart). For each induction frequency,
normalized fEPSP slopes, measured at the end of recording from each of the two
populations of slices, are plotted. Numbers in parentheses represents the number of
recordings at each point. *denotes p = 0.016.
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We also examined the relative contribution of NMDARs composed of GluN2A
or GluN2B subunits to synaptic currents by measuring EPSC NMDAR before and after
application of the selective GluN2B antagonist, Ro-256981. The relative block was the
same regardless of genotype (Figure 2.4e).
During LTD there is some loss of postsynaptic density 95 protein (PSD-95)
from the synapses followed by endocytosis of AMPAR (Bhattacharyya et al., 2009).
Therefore, we used western blotting to examine if there was a change in PSD-95
expression in TRPM2 KO mice. Consistent with the change in AMPARs, we observed a
significant reduction in PSD-95 expression (Figure 2.5a). Previous reports link the level
of PSD-95 expression with AMPAR number without an overall change in synaptic
number (Bhattacharyya et al., 2009; Chen et al., 2011). We examined the total
expression of GluR1 in TRPM2 KO slices versus those from WT mice, and as
anticipated observed a reduction in the expression of GluR1 (Figure 2.5b). In contrast,
the expression levels of GluR2 and NMDAR subunits were the same regardless of
genotype (Figure 2.5b,c,).
To further explore the mechanism of the loss of NMDAR-dependent LTD in
TRPM2 KO mice we examined the activity of glycogen synthase kinase-3β (GSK-3β),
which is required for this form of LTD (Peineau et al., 2007; Peineau et al., 2009). We
compared the expression levels and phosphorylation of this kinase at Ser9, which is
indicative of inactivation of GSK-3β (Frame, Cohen, & Biondi, 2001). Expression of
GSK-3β was unaltered; however, there was an increase in Ser9 phosphorylation (GSK3β inactivation) in TRPM2 KO slices (Figure 2.5d) suggesting that impaired LTD in
TRPM2 KO mice results from inhibition of GSK-3β (Peineau et al., 2007).
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Figure 2.4. AMPA/NMDA Receptor Contribution to EPSCs, and mEPSC
amplitude are diminished in TRPM2 KO slices.
(a) The ratio of AMPAR- to NMDAR-mediated EPSCs is reduced in TRPM2-/neurons. (b,c,d) Representative mEPSC traces (b) and summary bar graphs
demonstrating that the amplitude (c), but not the frequency (d) of mEPSCs is reduced in
slices from TRPM2 KO mice; (e) The relative contribution of GluN2B NMDAR
subtype to NMDAR EPSC, quantified by application of the selective antagonist Ro 256981, is unaltered in TRPM2 KO slices, confirming previous results in culture.
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Insulin also acts via stimulation of Akt/PKB to inactivate GSK-3β via Ser9
phosphorylation, resulting in a long lasting depression of AMPAR-mediated synaptic
transmission, which in turn occludes low frequency induced LTD (Man et al., 2000).
We therefore examined the effect of insulin on WT and TRPM2 KO slices. The longlasting depression induced by applications of insulin was lacking in TRPM2 KO slices
(Figure 2.5e) suggesting that insulin-induced LTD was occluded in this genotype due to
the pre-existing inactivation of GSK-3β. To determine if the loss of LTD in TRPM2 KO
is attributable to the consistent inhibition of GSK-3β we applied the D2 agonist
quinpirole in order to stimulate Akt GSK-3β signaling (Beaulieu, Gainetdinov, &
Caron, 2007) and observed an enhanced activation of GSK-3β (Figure 2.5f) and rescue
of LTD in TRPM2 KO mice (Figure 2.5g).

2.4 Discussion
Our results show that loss of TRPM2 expression modifies NMDAR-dependent
synaptic plasticity, specifically LTD, but they do not implicate TRPM2 channels
directly in excitatory synaptic transmission. Instead, the presence of TRPM2 channels
seems to be associated with maintenance of the appropriate level of GSK-3β activation
as well as full expression of PSD-95 and AMPARs. In the absence of the TRPM2
expression there is a reduction in the relative contribution of AMPA receptors to
synaptic transmission at CA1 synapses along with a reduction of LTD and a shift to
lower thresholds for the induction of LTP. This metaplastic shift towards LTP in
TRPM2 KO slices seems to result from enhanced phosphorylation and inactivation of
GSK-3β.
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Figure 2.5 Inhibition of GSK-3β phosphorylation and reduced PSD-95 and
AMPAR expression contributes to impaired LTD in TRPM2 KO mice.
The expression of (a) PSD-95 (normalized to β-actin loading control) and (b) the
AMPAR subunit, GluR1, is depressed in slices from TRPM2 KO mice. (b,c) Expression
of the AMPAR subunit, GluR2, and the NMDAR subunits GluN2A, GluN2B, and
GluN1 are unchanged in the absence of TRPM2; (d) Knockout of TRPM2 is correlated
with an increase in GSK-3β phosphorylation at its inhibitory site (Ser9, n = 3); (e)
Insulin application to hippocampal slices depresses AMPAR-mediated fEPSPs in slices
from TRPM2 KO, but not WT, slices. (f) Simulation of dopamine D2 receptors by
quinpirole (10 µM) reduces GSK-3β phosphorylation at Ser9 (n = 3); (g) D2 receptor
stimulation by quinpirole rescues LTD in slices from TRPM2 KO mice.
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The resulting inactivation of GSK-3β prevented further depression of synaptic
transmission by applications of insulin. Importantly, applications of quinpirole reduced
GSK-3β phosphorylation in TRPM2 KO slices and effectively rescued LTD induction
by repetitive low-frequency stimulation. Moreover, acute block of TRPM2 function by
clotrimazole prevented LTD induction thereby mimicking TRPM2 loss of function by
genetic deletion. Collectively, these findings argue that the reductions in GSK-3β
activity, PSD-95 and GluR1 expression, as well as AMPAR-mediated synaptic
transmission and plasticity observed in hippocampal slices derived from TRPM2 KO
mice cannot simply be attributed to developmental compensations resulting from
genetic deletion of TRPM2. Rather, in light of our findings, we propose that ongoing
TRPM2 channel activity contributes to the regulation of AMPAR-mediated fast
excitatory synaptic transmission through maintenance of constitutive GSK-3β activity.
The precise mechanism through which TRPM2 activity regulates GSK-3β
remains to be determined; however the contribution of TRPM2 to Ca2+ signaling is
likely to play an important role is this regard. Previous findings have proposed the Ca2+
dependent phosphatase, calcineurin (or PP2B), as a candidate for mediating dephosphorylation of GSK-3β at Ser9 (Y. Kim et al., 2009). Alternatively, the Ca2+dependent tyrosine kinase Pyk2 has been shown to associate and regulate GSK-3β
activity through tyrosine phosphorylation (Sayas et al., 2006). Whether the activity of
either calcineurin, Pyk2, or other kinases or phosphatases are altered by TRPM2initiated Ca2+ signaling remains to be established. Similarly, the behavioural
consequence of altered synaptic transmission and plasticity associated with the loss of
TRPM2 function has yet to be investigated; however, a recent paper by Kim and
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colleagues (2011) may offer some insight. These authors demonstrated that behavioural
flexibility, evaluated by reversal learning in the Morris water maze and by the delayed
non-match to place T-maze task, was reduced following genetic disruption of PI3Kγ,
which also resulted in a selective loss of NMDAR dependent LTD (J. I. Kim et al.,
2011). Additional research is required to assess whether these behaviours are similarly
altered in TRPM2 KO mice.

Conclusions
The present study establishes that loss of TRPM2 function through genetic
means provokes long lasting changes in excitatory synaptic transmission and plasticity
at the CA3-CA1 hippocampal synapse. Specifically, we show that the ability to induce
NMDAR-dependent LTD is impaired in TRPM2 KO mice. Such impairment was
associated with increased phosphorylation and inactivation of GSK-3β. Consistent with
previously reported changes associated with GSK-3β inhibition, we report reduced
PSD-95 and GluR1 expression and identify a corresponding reduction in AMPARmediated synaptic transmission. Interestingly, both GSK-3β and TRPM2 channels have
been implicated in a number of overlapping pathophysiological processes ranging from
pancreatic insulin secretion to Alzheimer’s disease (Bhat, Budd Haeberlein, & Avila,
2004; Takahashi et al., 2011). Accordingly, our results show the importance of continuing studies to determine the pathophysiological roles of GSK-3β and TRPM2 in
neurodegenerative diseases (Jo et al., 2011).
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3. Loss of glutathione homeostasis associated with neuronal senescence facilitates
TRPM2 channel activation in cultured hippocampal pyramidal neurons

3.1 Introduction
Aging is a major risk factor for developing several neurodegenerative diseases.
Although the precise reasons are poorly understood, a growing body of evidence
suggests that age-related cognitive decline is associated with stereotypic changes in
cellular homeostasis which ultimately lead to impaired neuronal function (Thibault,
Gant, & Landfield, 2007). A leading hypothesis suggests that increased oxidative stress
associated with aging predisposes neurons to dysregulated intracellular calcium (Ca2+)
homeostasis in response to disease causing factors (Camandola & Mattson, 2011).
Accordingly, understanding the relation between oxidative stress and altered Ca2+
homeostasis

may

provide

valuable

insight

into

mechanisms

underlying

neurodegenerative disease. Glutathione (GSH), the most abundant intracellular reducing
agent (Cooper & Kristal, 1997), plays an important role in limiting cellular damage by
reactive oxygen and nitrogen species generated as a by-product of aerobic metabolism.
Cellular levels of GSH are known to decrease with age (Chen, Richie, & Lang, 1989;
Liu, 2002; Parihar, Kunz, & Brewer, 2008; Rebrin, Forster, & Sohal, 2007; Sasaki et
al., 2001) and the resulting decline in antioxidant defence is viewed as a risk factor
contributing to the increased susceptibility to neurodegenerative disease associated with
aging. For example, a strong relationship has been demonstrated between reduced levels
of GSH and Parkinson’s disease (M. F. Anderson & Sims, 2002; Bragin et al., 2010;
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Martin & Teismann, 2009; Perry, Godin, & Hansen, 1982; Rehncrona & Siesjo, 1979;
Sian et al., 1994). Furthermore, a reduction in glutathione has also been associated with
cerebral ischemia (M. F. Anderson & Sims, 2002; Bragin et al., 2010; Rehncrona &
Siesjo, 1979; Salemi et al., 2009). Importantly, depletion of GSH itself leads to
increased oxidative stress, altered Ca2+ homeostasis and increased neuronal cell death
(de Bernardo et al., 2004; Khanna et al., 2003; Naziroglu et al., 2011; Wullner et al.,
1999). It is unknown whether depletion of GSH promotes Ca2+ dysregulation directly
(e.g. by altering Ca2+ permeation pathways) or through the induction of oxidative stress.
TRPM2 is a highly unique calcium permeable non-selective cation channel that
is responsive to reactive oxygen and nitrogen species (ROS/RNS). Channel activation
by ROS/RNS is proposed to occur following the generation of adenosine diphosphate
ribose (ADPR), which serves as an intracellular agonist (Sumoza-Toledo & Penner,
2011). Notably, gating is also greatly facilitated by elevated concentrations of
intracellular Ca2+ (McHugh et al., 2003; Olah et al., 2009). TRPM2 expression is
highest within the brain (Fonfria et al., 2006) and recent work in our lab demonstrated
that TRPM2 is expressed and functional in pyramidal neurons of the hippocampus
(Olah et al., 2009), a subset of neurons that are particularly susceptible to oxidative
stress-induced damage in stroke and neurodegenerative disease (Mattson, Guthrie, &
Kater, 1989; X. Wang & Michaelis, 2010). This current was absent in primary
hippocampal neurons cultured from TRPM2 knockout (KO) animals (Xie et al., 2011).
Importantly, TRPM2 has been shown to contribute to cell death in response to
oxidative stress, TNFα, amyloid-β peptide, and ischemia (Fonfria et al., 2005; Jia et al.,
2011; Takahashi et al., 2011). These findings raise the possibility that TRPM2 may
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play an important role in neurological diseases associated with aging, excitotoxicity
and oxidative stress.
Recent evidence suggests that TRPM2 channels may be directly regulated by
GSH. Indeed, GSH has been shown to inhibit TRPM2 currents in astrocytes,
microglia, and dorsal root ganglion sensory neurons (Lee et al., 2010; Naziroglu et al.,
2011). Importantly, these papers did not investigate the effects of glutathione on
TRPM2 channels in neurons susceptible to degeneration. Furthermore, the mechanism
responsible for the observed inhibition was not explored.
We now extend previous findings demonstrating GSH-mediated inhibition of
TRPM2 currents by demonstrating that intrinsic, age-dependent, variations in the
intracellular concentration of GSH is a key determinant in dictating the level of
TRPM2 activation in neurons. Moreover, we demonstrate that the inhibition of
TRPM2 function by GSH operates independently of its capacity as a reducing agent.
These findings suggest that altered intracellular Ca2+ dynamics associated with GSH
depletion, induced experimentally or with aging, may develop as a result of altered
TRPM2 regulation.

3.2 Methods
Reagents
Trypsin-EDTA, 5-fluorodeoxyuridine, uridine, CsOH, Gluconic acid, MgCl2,
CaCl2, BaCl2, EGTA, KCl, Mg-ATP, N-methyl-D-aspartate (NMDA), D-serine,
Glucose, Glutathione (GSH), L-Buthionine sulfoximine (L-BSO), and N-acetyl-cysteine
(NAC) were all purchased from Sigma (Oakville, Ontario, Canada). HEPES and NaCl
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were purchased from Bioshop (Burlington, Ontario, Canada). Ophthalmic acid was
obtained from Bachem (Bubendorf, Switzerland).
Cell culture
Mouse hippocampal primary neuronal cultures were prepared from CD-1
mice (Charles River, Wilmington, MA, USA) at E17-19 as described previously
with minor adjustments (MacDonald, Mody, & Salter, 1989). Briefly, hippocampal
tissue from embryonic day 17-18 mice were dissected, enzymatically and
mechanically dissociation with 0.05% Trypsin-EDTA, and plated at a density of < 1
6

−1

× 10 cells ml

on collagen coated Nunc™ 35 mm culture dishes (Fisher,

Rochester, NY). After 3-5 days, each plate was treated for 24hours with 0.08 mM 5fluorodeoxyuridine and 0.2 mM uridine. Cells were maintained for 4 weeks in
culture.
Whole-cell recordings: Primary culture
Currents were recorded from mouse hippocampal primary neuronal cultures at
14-28 days in vitro. Whole-cell voltage-clamp recordings were performed as described
previously, with minor adjustments (Olah et al., 2009). Unless otherwise indicated,
standard intracellular solution (ICS) contained (in mM): 150 cesium gluconate, 10
Hepes, and 2 MgCl2 and 1 ADPR. Standard extracellular solution (ECS) contained (in
mM): 140 NaCl, 5.4 KCl, 25 Hepes, 33 glucose, 2 CaCl2, and 0.2 TTX. TRPM2
currents were generated with either repeated NMDAR activation or voltage ramps.
NMDA currents were elicited with 100 µM NMDA and 3 µM d-serine added to the
standard ECS and applied for 5 or 10 seconds every minute using a multibarrelled rapid
perfusion system (SF-77B; Warner Instruments, Hamden, CT, USA). Voltage ramps
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(±100 mV, 1/10 sec) were applied in the presence of standard ECS supplemented with 1
mM MgCl2 and 1 mM BaCl2. After the TRPM2 current stabilized, or after 10 minutes
of recording, calcium free solution was applied (total divalent concentration was
maintained by replacing CaCl2 with equimolar BaCl2). Data were filtered at 2 kHz,
digitized, and acquired using pCLAMP and Axoscope software (Molecular Devices,
Sunnyvale, CA, USA).
Whole-cell recordings: TRPM2-HEK293
HEK293 cells stably expressing an inducible flag-tagged human TRPM2
(TRPM2-HEK293) were generously provided by Dr. A. M. Sharenberg (University of
Washington, Seattle, Washington). Cells were cultured at 37°C with 5% CO2 in
DMEM

(Sigma)

supplemented

with

10%

fetal

bovine

serum

and

1%

penicillin/streptomycin (Invitrogen, Burlington, ON, Canada). TRPM2 expression was
induced with doxycycline (1 µg ml-1) 24 hours prior to experiments. Intracellular
solution (ICS) contained (in mM): 130 CsGluconate, 10 HEPES, 2 MgCl2, 1 CaCl2, 10
EGTA, and 4 Mg-ATP. ICS was adjusted to a pH of 7.3 and osmolarity between 295
and 300 mOsm. The final resistance of ICS-filled electrodes was between 3 and 5 MΩ.
The standard extracellular solution (ECS) was composed of (in mM): 140 NaCl, 5.4
KCl, 25 HEPES, 33 glucose, 1 MgCl2, 2 CaCl2, pH of 7.4 and osmolarity between 310
and 315 mOsm. Calcium-free ECS contained 2 mM BaCl2 in the place of CaCl2. Data
were filtered at 2 kHz, digitized, and acquired using pCLAMP and Axoscope software
(Molecular Devices). TRPM2-HEK293 cells were held at -60 mV during whole-cell
voltage-clamp recordings. Currents were evoked through the intracellular application of
ADPR at a concentration of 0.1 mM unless otherwise indicated. Calcium containing
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ECS was applied for 5 minutes or until a current of -1000pA developed, followed by 23 minutes in calcium-free ECS. Calcium solution was then applied until the TRPM2
current began to inactivate, and the amplitude of the TRPM2 current was then
determined after removal of extracellular Ca2+.
Real-time quantitative polymerase chain reaction (QRT-PCR)
Total RNA was extracted from primary mouse hippocampal cultures at 15, 22,
and 29 days in vitro (DIV) with Trizol™ (Invitrogen, Burlington, Canada) according to
the manufacturer’s protocol. RNA concentration was quantified using the Nanodrop
Spectrophotometer ND1000 (Nanodrop technologies Inc., Wilmington, DE, USA). The
OD260/280 ratio for all samples was greater than 1.7. Following quantification, RNA
was reverse transcribed using Superscript™ II RT reagent according to the
manufacturer’s guidelines, including the optional treatment with 40 units of
RNaseOUT™ (Invitrogen). “No RT” controls contained 1 µL H2O instead of
Superscript™ II RT reagent. The reaction was carried out in an Eppendorf
Mastercycler personal (Hamburg, Germany).
Primers were designed against the mouse TRPM2 coding strand (accession
number NM_138301) and purchased from Sigma. To test primer efficiency, a
standard curve was constructed from mouse hippocampal total cDNA using 10x
serial dilutions, ranging from 100 ng to 0.1 ng. Inclusion criteria for primers were
2

an efficiency of 90-110%, and an R value >0.98.
To quantify TRPM2 mRNA, 100 ng of cDNA from each sample was run in
duplicate with iQ™ SYBR green Supermix (Biorad, Mississauga, Ontario) according to
the manufacturer’s instructions. The BioRad MyiQTM iCycler was used for real-time
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qPCR. Negative controls included the No RT samples from reverse transcription and a
no-template control containing water instead of cDNA. Biorad MyIQ™ 2.0 software
was used for quantification of cycle threshold. TRPM2 primers produced a 90 bp
amplicon

using

the

sense

sequence

5’TGATCCTGATGGCTGTGGAC3’

in

combination with antisense sequence 5’AAGAGCAGAATGGCCCCA3’. The reaction
was carried out at 95°C for 3minutes, followed by 40 cycles of 95°C for 1 minute and
55°C for 30 seconds. To control for potential variation in the number of neurons present
in culture, cycle thresholds for TRPM2 mRNA were normalized to neuron specific
enolase (ENO2) using the sense primer sequence 5’CTGCCTCTGAGTTTTACCGC3’
and the antisense primer sequence 5’TCCGGACAAAGTCCTGGTAG3’. ENO2 was
quantified with a thermal profile of 95°C for 3 minutes, followed by 40 cycles of 95°C
for 1 minute and 62°C for 30 seconds. A dissociation curve was run for both primers
using the following thermal profile: 95°C for 1 minute, 55°C for 1 minute, followed by
a 2°C steps every 10 seconds from 70°C to 95°C.
Statistics
Data are expressed as mean ± SEM. Statistical analysis was undertaken
using GraphPad Prism® (GraphPad Software, San Diego, CA). An unpaired twotailed t-test, a one-way ANOVA followed by a Tukey’s HSD post-hoc test, or a
two-way ANOVA followed by Bonferroni post-hoc test was used to assess
statistical significance. Data was considered significant when p < 0.05.
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3.3 Results
TRPM2 currents increase with time in vitro
Primary neuronal cultures are often used to examine neuronal development;
however, beyond 21 days in vitro, early neuronal markers such as nestin drastically
diminishes in expression, and mature neuronal markers such as MAP-2 are expressed,
indicative of a mature neuronal population (Bertrand et al., 2011). Furthermore, cultures
maintained beyond 3 weeks in vitro recapitulate many of the characteristic cellular
changes that have been associated with aging and neurodegeneration (Aksenova et al.,
1999; Bertrand et al., 2011; Kim et al., 2007; Lesuisse & Martin, 2002). These include
increased oxidative stress, lipid peroxidation, protein tyrosine nitration, mitochondrial
injury, ER stress, DNA damage, Ca2+ dysregulation, calpain cleavage, endogenous Aβ
accumulation, and susceptibility to neuronal cell death.
Importantly, in primary neuronal cultures the concentration of GSH has also
been shown to decrease with time in vitro (Keelan et al., 2001; Sagara, Miura, &
Bannai, 1993). Accordingly, long-term neuronal cultures serve as a valuable model
system for the study of cellular changes associated with neuronal aging and
senescence. With this in mind, we first sought to determine whether in vitro neuronal
senescence correlates with altered TRPM2 function.
To rigorously examine TRPM2 function over time in culture, whole-cell
voltage-clamp recordings were made from primary hippocampal neuronal cultures
maintained in vitro for up to 28 days. Using a previously established protocol (Olah et
al., 2009), TRPM2 currents were evoked by intracellular administration of ADPR
paired

with

repeated

N-methyl-D-aspartate

receptor

(NMDAR)

stimulation.
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Importantly, the currents generated using this protocol can be entirely attributed to
TRPM2 channels as they are abolished by known blockers of TRPM2 (Olah et al.,
2009). To ensure that the full complement of TRPM2 channels expressed at various
time points are being activated in our recordings, a saturating concentration of ADPR (1
mM) was included in the patch pipette. Furthermore, as the neuronal cell surface area
increases over time due to the continued extension of neuronal processes, TRPM2
currents were normalized to membrane capacitance, measurement of which correlates
with cell surface area (p < 0.05, data not shown). As illustrated by the representative
traces shown in Figure 3.1A and 2.1B, repeated applications of NMDA to pyramidal
neurons loaded with ADPR caused the progressive development of large inward
currents, the amplitudes of which stabilized within approximately 5-15 min. The
amplitude of TRPM2 currents was then determined after removal of extracellular Ca2+,
a protocol known to abolish TRPM2-mediated currents (Olah et al., 2009; Xie et al.,
2011). Recordings were made from neurons at 14, 20, and 26 days in vitro (DIV, n =
5/group). Results demonstrate that there is an increase in TRPM2 current density
between 14 and 26 DIV in cultured hippocampal pyramidal neurons (Figure 3.1C, p <
0.05). Since activation of the NMDAR was used to elicit the TRPM2 current, we also
analyzed whether the NMDAR current density is increased over time in vitro. No
change was observed over this same time period (p = 0.76, Figure 3.1D). Furthermore,
we assessed whether a change in NMDAR kinetics may explain the enhanced TRPM2
response by calculating the integral under the NMDAR application and normalized this
measurement to capacitance (Q/pF). Similarly, no change was observed from 2 – 4
weeks in vitro (data not shown, p = 0.39).
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Figure 3.1. TRPM2 currents are enhanced in hippocampal pyramidal neurons
with time in vitro. With 1 mM ADPR included in the patch pipette, TRPM2 currents
developed slowly following repeated (1/60 sec) applications of NMDA (100 µM, for 5
sec). TRPM2 currents were quantified by removing extracellular calcium and amplitude
was normalized to cell capacitance. NMDA applications are indicated with solid lines.
Calcium-free application is depicted as a dashed line (A) Representative trace of
TRPM2 currents recorded at 14 DIV (B) Representative trace of TRPM2 currents
recorded at 25 DIV. (C) Current density at 14, 20 , and 26 DIV (n = 5 per group) were
compared by one-way ANOVA followed by post-hoc Tukey`s test. A significant
increase in TRPM2 current density between 14 and 26 DIV was observed (p < 0.05).
(D) NMDAR current density is not significantly increased over time in vitro (p = 0.76).
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TRPM2 mRNA does not change with time in vitro
Increased TRPM2 current density with time in vitro could be attributed to an
increase in the function of TRPM2, potentially via a decrease in glutathione, or
alternatively an increase in TRPM2 expression. Using real-time quantitative PCR (RTQPCR), we tested whether TRPM2 mRNA increases with time in vitro in primary
hippocampal cell culture. Total RNA from cells at 15 (n = 9), 22 (n = 8), and 29 (n = 9)
DIV were run in duplicate and TRPM2 levels were quantified.
Results were normalized to neuron-specific enolase (Eno2) by calculating delta
cycle threshold (∆CT) values for each sample (NSE CT – TRPM2 CT) in order to
control for any variability in neuronal content over time. Analysis by one-way ANOVA
revealed no change in the TRPM2 cycle threshold (p = 0.89, Figure 3.2A), Eno2 (p =
0.9, Figure 3.2B) or normalized TRPM2 mRNA levels over time in vitro (p = 0.51,
Figure 3.2C). These findings demonstrate that changes in mRNA expression levels are
not responsible for the increase in TRPM2 current density observed over time in vitro.

Modulation of GSH alters TRPM2 currents in hippocampal pyramidal neurons
If decreased cellular GSH content is responsible for elevated TRPM2 function
over time in vitro, then enhancing intracellular GSH levels should diminish TRPM2
current amplitude in older cultured neurons (~28 DIV). Conversely, reducing
intracellular GSH levels should facilitate TRPM2 channel function in younger
neuronal cultures (~14 DIV).
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Figure 3.2. TRPM2 mRNA levels do not change in hippocampal primary cultures
with time in vitro. (A) TRPM2 mRNA was measured at 14, 21, and 29 DIV (n=8 per
group) by quantitative real-time PCR (qPCR). No significant change in cycle threshold
values is observed (p = 0.89) (B) QPCR analysis of neuron specific enolase (ENO2)
mRNA values used to control for neuronal content over time. No significant difference
was observed (p = 0.9). (C) Normalized TRPM2 values for each sample (ENO2TRPM2) were quantified. No difference in the normalized levels of TRPM2 mRNA is
seen over time in culture (p = 0.51).
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We first examined the consequence of elevating the intracellular concentration
of GSH in neurons at 4 weeks in vitro by exogenous application through the patch
pipette. When compared with controls, GSH (10 mM) significantly inhibited TRPM2
currents activated in the presence of ADPR by the NMDAR stimulation protocol
(Figure 3.3A, p = 0.04). In millimolar concentrations, extracellular GSH has been
shown to enhance NMDAR function (Kohr et al., 1994; Oja et al., 2000). No difference
in NMDAR amplitude was observed with intracellular delivery of GSH (p = 0.82, data
not shown). Representative traces are shown in Figure 3.3B (control) and C (10mM
GSH). To confirm the effects of GSH on TRPM2 currents, we also examined the effects
of GSH delivered through the patch pipette on TRPM2 currents generated by a voltage
ramp protocol. Using this alternative protocol, GSH similarly inhibited TRPM2 currents
(Figure 3.3D, p = 0.01). Examples of representative traces for control and GSH voltage
ramp recordings are shown in Figure 3.3E and 2.3F, respectively.
We next sought evidence that augmenting endogenous GSH content can
similarly decrease TRPM2 function. We chronically treated neurons from 1-4 weeks in
vitro with N-acetylcysteine (NAC), a precursor to GSH that has been shown to increase
levels of endogenous GSH (M. F. Anderson & Sims, 2002; Aoyama, Watabe, &
Nakaki, 2008; Gao et al., 2009; Jayalakshmi et al., 2005) and examined whether
TRPM2 currents in cultures at 4 weeks in vitro were reduced. Treatment with 50 µM
NAC beginning at 1 week in vitro significantly attenuated TRPM2 currents in cultures
at 28 DIV (p= 0.04, Figure 3.4A-C). Previous studies have shown that NAC is able to
act as a reactive oxygen scavenger independent of its ability to upregulate GSH
(Aruoma et al., 1989).
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Figure 3.3. GSH inhibits TRPM2 currents in hippocampal pyramidal neurons.
(A) 10 mM GSH in the patch pipette significantly inhibits TRPM2 currents generated
by 1 mM ADPR with an NMDAR stimulation protocol (p = 0.04). (B, C)
Representative traces of control and GSH inhibition with the NMDAR stimulation
protocol. (D) 10 mM GSH in the patch pipette significantly inhibits TRPM2 currents
generated by 1 mM ADPR with a voltage ramp protocol (p = 0.01). (E,F)
Representative traces of control and GSH inhibition with the voltage ramp protocol
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To confirm that the observed effect can be attributed to GSH and not to NAC itself,
NAC (50 µM) was included in the patch pipette and TRPM2 currents were elicited with
the NMDA activation protocol with 1 mM ADPR in the patch pipette. Compared to
controls (1076 ± 204.9, n = 3), acute NAC (910.5 ± 142.8 n = 4) did not alter TRPM2
currents (p= 0.52, data not shown). These results confirm previous findings that GSH
can inhibit TRPM2 currents, and are consistent with the notion that reduced GSH, at
least in part, may underlie the increase in TRPM2 currents that we observed in
hippocampal pyramidal neurons over time in vitro. These findings also imply that GSH
constitutively suppresses TRPM2 function in younger cultured neurons.
Accordingly, we next examined whether depleting GSH could augment TRPM2
function in young cultures maintained for 2 weeks in vitro. L-buthionine-(S,R)sulfoximine (L-BSO) inhibits the enzyme γ-glutamylcysteine synthetase, the rate
limiting step in GSH synthesis (M. E. Anderson, 1998) and is effective in depleting
GSH (M. F. Anderson & Sims, 2002; Aoyama et al., 2008; Keelan et al., 2001; Sebastia
et al., 2003; Wullner et al., 1999). Consistent with our hypothesis, TRPM2 currents
were significantly potentiated, when compared with controls (p= 0.01), in 2 week old
cultured neurons depleted of GSH by treatment with 250 µM L-BSO for 48 hours
(Figure 3.4D-F).
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Figure 3.4. Modulation of Endogenous GSH Alters TRPM2 Currents
(A)

Treatment from 1-4 weeks in vitro with 50 µM NAC significantly inhibited

TRPM2 currents generated by 0.3 mM ADPR and an NMDAR stimulation protocol in
cultures at 28 DIV (p= 0.04). (B, C) Representative control and NAC traces. (D) A 48
hour treatment with 250 µM L-BSO significantly enhances TRPM2 currents generated
with 1 mM ADPR with an NMDAR stimulation protocol in hippocampal pyramidal
neurons at 2 weeks in vitro. (E, F) Representative control and L-BSO traces.
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Mechanism of TRPM2 inhibition by GSH
HEK293 cells stably expressing TRPM2 under control of an inducible
promoter (TRPM2-HEK293) were used to characterize the mechanism of GSHmediated TRPM2 inhibition. To further validate our findings in hippocampal
pyramidal neurons, and previous findings in glial and dorsal root ganglion cells
[20,31], TRPM2 currents from TRPM2-HEK293 cells were recorded in the whole-cell
patch clamp configuration with 0.1 mM ADPR in the patch pipette. Of note, HEK293
cells do not express NMDARs nor voltage-gated Ca2+ channels. In these cells,
intracellular application of ADPR alone is sufficient to activate TRPM2 channels in
this model system, presumably due to the much higher induced channel expression.
Currents generated under control conditions were compared to those generated when
10 mM GSH was included in the patch pipette, and removal of extracellular Ca2+ was
used to abolish the TRPM2 current. In these cells, intracellular delivery of GSH
substantially attenuated the TRPM2 current (Figure 3.5, p < 0.001).
GSH may regulate channel function through a number of distinct mechanisms
including redox mechanisms, or post-translational modification involving the
formation of mixed protein disulfides (i.e. glutathionylation). Through its reducing
potential GSH has been shown to regulate the function of other receptors and
channels, including NMDARs (Bodhinathan, Kumar, & Foster, 2010; Kohr et al.,
1994). To examine the possibility that TRPM2 is regulated through changes in its
redox state, we examined whether the inhibitory effect of GSH could be mimicked by
another reducing agent, dithiothreitol (DTT). DTT was included in the patch pipette
and currents were recorded from TRPM2-HEK293 cells. At 10 mM DTT, no change
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in TRPM2 amplitude was observed when compared to controls (p > 0.05; Figure 3.5),
suggesting that the reducing ability of GSH is not responsible for the change in
TRPM2 currents.

98

Figure 3.5. GSH inhibits TRPM2 in a thiol-independent mechanism. TRPM2
currents were elicited in HEK293-TRPM2 cells using a 2mM calcium extracellular
solution and 0.1mM ADPR. TRPM2 currents were then inhibited and quantified
following removal of extracellular calcium (A) Representative TRPM2 responses
obtained in control (n=12), GSH (n=10), DTT (n=6) and ophthalmic acid (n=6) groups
(B) TRPM2 currents are significantly inhibited with 10 mM GSH or 10 mM ophthalmic
acid, but are not altered when 10 mM DTT is included in the patch pipette (One-way
ANOVA followed by post-hoc Tukey’s test, * p < 0.05).
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GSH has also been shown to inhibit currents through direct binding to
channels, either at thiol residues, known as glutathionylation, or at other non-thiol
containing binding sites (Herson & Ashford, 1999; W. Wang et al., 2005; Yang et al.,
2010). Ophthalmic acid (γ-glutamyl-2-amino-n-butanoylglycine) is an analogue of
GSH which contains L-2-aminobutyrate in place of the cysteine residue (WALEY,
1958). This analogue lacks both the ability to form disulphide bonds and the reducing
potential of GSH. Interestingly, when ophthalmic acid (10 mM) was included in the
patch pipette, TRPM2 currents were significantly inhibited in TRPM2-HEK293 cells
(p < 0.001; Figure 3.5). This demonstrates that GSH acts in a thiol-independent
manner to inhibit TRPM2 currents.
Potential mechanisms of TRPM2 inhibition by GSH were further studied by
constructing a concentration-response relationship for ADPR with or without 10 mM
GSH included in the patch pipette. TRPM2 currents were evoked with varying
intracellular concentrations (0.03 - 3 mM) of ADPR. Each point on the curve
represents the mean +/-SE of 6 -11 recordings (Figure 3.6). A two-way ANOVA
followed by Bonferroni post-hoc test revealed an overall significant effect, with a
highly significant inhibition by GSH for TRPM2 currents evoked with ADPR
concentrations of 0.1, 0.3, and 1 mM (p < 0.001). No difference between groups was
observed at the highest (3 mM) and lowest (0.03 mM) ADPR concentrations (p >
0.05). In control conditions, the EC50 of ADPR was 77 µM, consistent with a previous
report (Perraud et al., 2001). In contrast, the EC50 of ADPR with 10 mM GSH was
269 µM, representing a ~3.5 fold change in sensitivity when GSH is included in the
patch pipette.
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Figure 3.6. GSH shifts the ADPR concentration-response curve of TRPM2
channels by 3.5 fold. TRPM2 currents were generated with or without 10 mM GSH
included in the patch pipette. Intracellular concentrations of ADPR used to evoke the
current ranged from 0.03 – 3mM. Each point on the curve represents the mean +/- SE of
6 – 11 recordings. Significant inhibition by GSH was observed for TRPM2 currents
evoked by ADPR concentrations of 0.1, 0.3, and 1 mM (p<0.001), with no difference
between groups at the highest (3 mM) and lowest (0.03 mM) ADPR concentration
points (p>0.05). The EC50 value for ADPR was increased from 77 µM (control) to 269
µM (10 mM GSH) in the presence of 10 mM GSH, representing a ~3.5 fold change in
sensitivity to ADPR. Concentration-response curves were fit using a sigmoidal
concentration-response (variable slope), with a Hill slope of 2.2 in control, and 0.9 in
the GSH data set.
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The concentration–response curves fit using a sigmoidal concentration–
response (variable slope), results in a Hill slope of 2.2 in control, and 0.9 in the GSH
data set. The rightward shift in the concentration-response relationship and decrease in
the Hill coefficient confirm that GSH inhibits TRPM2 channels. The results with DTT
and ophthalmic acid confirm that the effects of GSH are thiol independent. However,
whether GSH functions as a channel blocker, competes for the ADPR binding site, or
interferes with TRPM2 currents by binding to ADPR requires further investigation.

3.4 Discussion
In this study we demonstrate that TRPM2 function increases with time in
vitro in cultured hippocampal pyramidal neurons. Moreover, we show that by
altering the intracellular concentration of GSH TRPM2 current amplitude can be
modulated in this system. Specifically, this was shown in experiments where GSH
was supplied exogenously through the patch pipette, or alternatively, where we
modulated endogenous GSH metabolism. We also demonstrate that ophthalmic
acid, but not DTT, is able to recapitulate GSH mediated inhibition of TRPM2
currents, suggesting that GSH inhibits TRPM2 channels independently of its
electron-donating capacity. Lastly, a 3.5-fold shift in the concentration-response
curve and decrease in the Hill coefficient for ADPR generated TRPM2 currents
suggest that GSH either disrupts the co-operative interaction between ADPR and
TRPM2 or functions as a channel blocker. Further research is required to determine
the precise nature of this interaction. The mechanism through which GSH inhibits
TRPM2 and its relevance to the regulation of the channel in neurons is crucial to
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understanding the pathways leading to neurotoxicity.
TRPM2 is a Ca2+ permeable non-selective ion channel implicated in oxidative
stress-induced cell death (Fonfria et al., 2005; Jia et al., 2011; Takahashi et al., 2011).
Several factors have been reported to modulate TRPM2 current response including Ca2+
concentration, temperature, pH, phosphorylation, the epilepsy related protein EFHC1,
and CD38 (Katano et al., 2012; Numata et al., 2012; Takahashi et al., 2011). Recently,
TRPM2 currents were shown to be inhibited by GSH in sensory neurons (Naziroglu et
al., 2011) as well as in glial cells, where TRPM2 activation following chemically
induced GSH depletion contributes to neuroinflammation (Lee et al., 2010; Naziroglu et
al., 2011). Our own findings now demonstrate that intrinsic alterations in endogenous
GSH content are associated with altered TRPM2 function in hippocampal pyramidal
neurons. Collectively, these studies suggest that GSH is a physiologically relevant
regulator of TRPM2 and that dynamic changes in GSH content are likely to be
associated with parallel changes in TRPM2 function. Importantly, a reduction in GSH
has been associated with normal aging in vivo (Chen et al., 1989; Liu, 2002; Rebrin et
al., 2007; Robillard et al., 2011; Sasaki et al., 2001). Neurodegenerative disorders,
including Parkinson’s disease and progressive supranuclear palsy, are associated with
enhanced depletion in intracellular GSH compared to age-matched controls (Martin &
Teismann, 2009; Perry et al., 1982; Sian et al., 1994). GSH depletion is also observed
following ischemia in animal models and in human subjects (M. F. Anderson & Sims,
2002; Bragin et al., 2010; Rehncrona & Siesjo, 1979; Salemi et al., 2009). Diminished
levels of reduced GSH has also been linked to bipolar disorder, major depressive
disorder, and schizophrenia (Do et al., 2000; Gawryluk et al., 2011). Importantly,
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upregulation of glutathione with NAC treatment protects against neuronal cell death in
vitro and in vivo (Andreassen et al., 2000; Clark et al., 2010; Henderson et al., 1996;
Jayalakshmi et al., 2005; Mayer & Noble, 1994; Morshead & van der Kooy, 2000;
Rothstein et al., 1994).
The findings in this manuscript raise the intriguing possibility that GSH
depletion

associated

with

aging,

ischemia,

and

several

psychiatric

and

neurodegenerative disorders, may be associated with enhanced TRPM2 channel
function. Future experiments will be required to assess whether TRPM2 currents are
also enhanced with age in vivo, and/or in models of neurological disease associated
with GSH depletion. Furthermore, the contribution of TRPM2 to neurodegeneration
and dysfunction associated with these conditions should be established. Interestingly,
depletion of GSH in Parkinson’s is one of the earliest biochemical markers of
impending neuronal degeneration (Martin & Teismann, 2009). Moreover, TRPM2 is
expressed and functional in dopaminergic neurons of the substantia nigra (Chung,
Freestone, & Lipski, 2011). Accordingly, whether TRPM2 currents are enhanced in
models of Parkinson’s disease (or other neurodegenerative disease in which GSH is
depleted) and whether knock-out of TRPM2 may attenuate neurodegeneration has yet
to be investigated. Importantly, neurodegenerative diseases are well known to be
associated with pronounced neuroinflammatory response. The demonstration that
GSH depletion in glial cells promotes neuroinflammation through a mechanism
involving TRPM2 (Lee et al., 2010), paired with our demonstration that GSH
depletion facilitates TRPM2 function in vulnerable hippocampal pyramidal neurons,
suggests that TRPM2 activation contributes to neuronal demise in neurodegenerative
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disease through multiple mechanisms. By extension, TRPM2 may represent an
important target for the development of novel therapeutic agents of benefit in the
treatment of these debilitating neurological diseases.
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4. Fyn kinase, Aβ, and TRPM2: Potential implications to Alzheimer’s Disease

4.1 Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a
prevalence of approximately 500,000 individuals in Canada, representing 1.5% of our
total population (Alzheimer Society of Canada, 2010). AD presents with degeneration
of the basal forebrain cholinergic neurons, entorhinal cortex, hippocampus and cortex
(Coyle, Price, & DeLong, 1983; Gomez-Isla et al., 1996). The degree of degeneration
and synaptic loss in these areas correlate strongly with the severity of dementia (Scheff
& Price, 2003).
Soluble oligomers of Aβ42 are believed to initiate the primary insult leading to
degeneration through modulation of a variety of pathways (Hardy & Selkoe, 2002). For
example, Aβ42 increases GSK-3β activity, which subsequently contributes to the
pathological hyperphosphorylation of tau (Hernandez, Lucas, & Avila, 2012; Hooper,
Killick, & Lovestone, 2008). Downregulation of endogenous tau attenuates neuronal
cell death and behavioural deficits in a mouse model of AD, demonstrating that
pathologically modified tau is critical for neurotoxicity in AD (Roberson et al., 2007).
Although the mechanism through which tau contributes to neurotoxicity is still under
investigation, recent evidence suggests that tau confers toxicity in AD, at least in part,
by targeting the non-receptor tyrosine kinase Fyn to NMDA Receptors (NMDARs)
(Ittner et al., 2010).
Exposure to a high concentration of Aβ induces a series of changes at the
cellular level including reduced excitatory synaptic transmission in the hippocampus,
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increased levels of intracellular Ca2+, and increased neuronal death (Huang & Mucke,
2012). Several studies have suggested that aberrant activation of NMDARs in response
to Aβ exposure could explain these phenomena (Alberdi et al., 2010; Hu et al., 2009;
Molnar et al., 2004; Ronicke et al., 2010). Importantly, Aβ oligomer exposure exerts a
dichotomous effect on excitatory synaptic transmission, enhancing transmission when
concentrations are low, and decreasing transmission when concentrations are high
(Puzzo, Privitera, & Palmeri, 2012). High concentrations of Aβ or prolonged exposure
have also been shown to decrease NMDAR amplitude and promote internalization of
NMDARs (Jacob et al., 2007; Kurup et al., 2010; Snyder et al., 2005). Furthermore,
clinical trials with the NMDAR antagonist memantine only produces a modest
improvement in moderate to severe AD, and marginal benefit in mild to moderate AD
(McShane, Areosa Sastre, & Minakaran, 2006). It is therefore unlikely that the tau-FynNMDAR complex can explain all of the toxicity observed in AD.
We propose that the Ca2+ permeable non-selective cation channel TRPM2 may
participate in this toxic protein complex. TRPM2 channels are activated by oxidative
stress, and have been shown to contribute to cell death in a variety of cell types
(Takahashi et al., 2011). Furthermore, the decrease in NMDAR amplitude induced by
Aβ requires the activation of another non-NMDAR inward current which, similar to
TRPM2, displays a linear I-V relationship (Snyder et al., 2005). Indeed, one previous
study demonstrated that knockdown of TRPM2 protected a striatal culture system from
cell death induced by 20µM monomeric Aβ (Fonfria et al., 2005). Although the
relevance to AD of striatal cultures and high concentrations of monomeric Aβ is
questionable, this study did provide the first evidence that TRPM2 may participate in
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AD. Furthermore, previous work in our lab has demonstrated that TRPM2 currents can
be activated by strong stimulation of NMDARs (Olah et al., 2009). We have also
demonstrated that TRPM2 interacts with the GluN1 subunit of NMDARs, and
inhibition of GluN2B containing NMDAR significantly attenuates TRPM2 current
development in cultured hippocampal neurons (M. Jackson & J. MacDonald,
unpublished). This data suggests a unique physical and functional relationship between
GluN2B containing NMDAR and TRPM2. We also previously demonstrated that
TRPM2 contributes to maintaining GSK-3β activity, raising the possibility that TRPM2
may play a role in the pathological alterations to tau (Xie et al., 2011). Lastly, a recent
study showed that TRPM2 is phosphorylated on tyrosine residues following exposure to
oxidative stress (Zhang et al., 2007). The influx of Ca2+ observed after exposure to
oxidative stress in TRPM2 expressing cells is reduced when cells are pretreated with
PP2, an SFK inhibitor (Zhang et al., 2007).
In humans, the SFK family consists of 9 members including Src, Fyn, Yes, Fgr,
Lck, Hck, Blk, Lyn, Frk. In this study, we focus on Fyn as a potential modulator of
TRPM2 function. Fyn is expressed at the post-synaptic density in neurons, and
modulates synaptic plasticity (Husi et al., 2000; Yang, Trepanier et al., 2011).
Furthermore, Fyn demonstrates enhanced activity and/or expression in response to
oxidative stress (Gao et al., 2009; Griendling et al., 2000; Sanguinetti, Cao, & Corley
Mastick, 2003). Fyn has also been shown to promote neurotoxicity in models of
Alzheimer’s disease (Chin et al., 2004; Chin et al., 2005; Ho et al., 2005; Ittner et al.,
2010; Lambert et al., 1998). Recently, our lab demonstrated that Fyn enhances GluN2B
containing NMDAR currents and favours long-term depression (LTD) (Yang, Trepanier
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et al., 2011). This finding is of particular importance because we have also shown that
TRPM2 activity is required for NMDAR-dependent LTD (Xie et al., 2011).
In the present study we expand upon the initial finding that TRPM2 participates
in Aβ mediated toxicity. We hypothesize that Aβ will enhance TRPM2 currents in
cultured hippocampal neurons. We further investigate the hypothesis that TRPM2 is
regulated by Fyn kinase by evaluating a potential physical and functional relationship
between Fyn and TRPM2. These results provide a novel pathway through which
TRPM2 activity is regulated, and also implicate TRPM2 in neurodegenerative
processes, such as AD, associated with Fyn kinase.

4.2 Methods
Cell Culture
Mouse hippocampal primary neuronal cultures were prepared from embryonic
day 17-18 mice. The hippocampus was dissected, enzymatically and mechanically
dissociated with 0.05% Trypsin-EDTA, and plated at a density of < 5 × 105 cells ml−1
on collagen coated Nunc™ 35 mm culture dishes (Fisher, Rochester, NY). Cells were
maintained for 4 weeks in Neurobasal medium (Invitrogen, Burlington, Ontario,
Canada), supplemented with B-27 (Invitrogen) and glucose (Sigma, Oakville, Ontario,
Canada).
Aβ Oligomer Preparation
Amyloid (r-peptide, Bogart, GA, USA) was prepared according to a previously
established protocol (Stine et al., 2003). Oligomerization of samples was confirmed by
separation on a 16.5% Tris-Tricine gel (Biorad), transfer to a nitrocellulose membrane,
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and detection of Aβ (Signet 6E10, 1:7000). Monomers, dimers, trimers, and tetramers
were detectable using these oligomerization condtions (Figure 4.1).
MTT Assay
An

MTT

(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium

bromide)

reduction assay was used to assess cell viability following Aβ oligomer exposure. The
assay was conducted according to manufacturer’s protocol with minor modifications.
Briefly, MTT reagent (Sigma) was dissolved to 5mg/mL in PBS. The solution was then
added to the cells at a concentration 50µg/mL for 1.5hours. Media was then removed,
and 1mL DMSO was added to the cells. Absorbance was measured at 595nM and
650nM.
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Figure 4.1 Amyloid Oligomers
Oligomerization of Aβ1-42 (15µL of 10µM prepared Aβ, r-peptide) was confirmed by
western blotting. Samples were separated on a 16.5% Tris-Tricine gel (Biorad),
transferred to a nitrocellulose membrane, and probed for Aβ (Signet 6E10, 1:7000).
Results indicate the presence of Aβ monomers, dimers, trimers, and tetramers.
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Whole-Cell Recordings: Cultured Hippocampal Neurons
Whole-cell voltage-clamp recordings were performed as described previously
(Olah et al., 2009). TRPM2 currents were generated with either repeated NMDAR
activation or voltage ramps. Briefly, patch electrodes were filled with an intracellular
solution (ICS) containing: 150mM cesium gluconate, 10mM Hepes, 2mM MgCl2, with
or without 0.3mM ADPR. Standard extracellular solution (ECS) contained 140mM
NaCl, 5.4mM KCl, 25mM Hepes, 33mM glucose, 2mM CaCl2.. Zero calcium ECS
contained 2mM BaCl2 in the place of CaCl2. For voltage ramp recordings, ECS was also
supplemented with 1mM BaCl2 and 1mM MgCl2. Voltage ramps (±100mV, 1/10sec)
were applied in the presence of Ca2+ containing ECF.. For NMDA-evoked TRPM2
currents, NMDA currents were evoked for 5 seconds every minute with standard ECS
supplemented with 100 µM NMDA and 3 µM d-serine, using a multibarrelled rapid
perfusion system (SF-77B; Warner Instruments, Hamden, CT, USA). For both
recording protocols, zero Ca2+ ECF was applied after the current was stable for at least
1 minute. Recordings were performed at a holding potential of -60mV at room
temperature (20–22°C) using a Multiclamp 700A amplifier (Molecular Devices,
Sunnyvale, CA). ECS was applied with a multibarrelled perfusion system (SF-77B;
Warner Institute, Hamden, CT, USA). Data were filtered at 2 kHz, digitized, and
acquired using pCLAMP and Axoscope software (Molecular Devices).
Whole-Cell Recordings: HEK293-TRPM2 Cells
HEK293 cells stably expressing an inducible flag-tagged human TRPM2
(HEK293-TRPM2) were generously provided by Dr. A.M. Sharenberg (University of
Washington, Seattle, Washington). Cells were maintained in DMEM (Sigma)
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supplemented with 10% fetal bovine serum (Invitrogen, Burlington, ON, Canada).
Doxycycline (1µg/mL) was used to induce TRPM2 expression 24 hours prior to
recording. ICS contained (in mM): 130 CsGluconate, 10 HEPES, 2 MgCl2, 1 CaCl2, 10
EGTA, and 4 Mg-ATP. ICS was adjusted to a pH of 7.3 and osmolality between 295300 mOsm. Standard ECS as listed above omitting TTX and D-serine, and including 1
MgCl2. Zero calcium ECS replaced the 2mM CaCl2 with BaCl2. Currents were evoked
through intracellular application of ADPR at a concentration of 0.1mM. Calcium
containing ECS was applied until a current of -1000 pA developed, followed by 2-3
minutes in zero calcium ECS. TRPM2 currents were then activated in the presence of
Ca2+ ECS until the current began to inactive. A second peak was generated following 5
minutes in zero Ca2+ ECS. No difference in amplitude was observed between the first
and second peak, so results presented in this report reflect data gathered from the first
TRPM2 response generated.
Fyn Constructs
Wild-type Fyn Construct
Fyn kinase (accession number NM_00237.3) was amplified from a human
cDNA library using KOD Hot Start DNA Polymerase (EMD Biosciences, San Diego,
CA) using primers listed in table 1 and thermal profile: 95°C for 2 minutes followed by
10 cycles at 94°C for 15 seconds, 60°C (-1°C/cycle) for 15 seconds, and 72°C for 40
seconds, and 25 cycles at 94°C for 15 seconds, 50°C for 15 seconds, and 72°C for 40
seconds. The PCR product was then run on a 1% w/v agarose gel plus 0.5µg/mL of
ethidium bromide (Sigma-Aldrich, Oakville, Canada). PCR product was extracted from
the agarose gel using a GenElute gel extraction kit (Sigma). A double restriction

122

enzyme digest with NotI and AscI (NEB, Ipswich, MA) was carried out at 37°C for 2
hours, followed by purification with GenElute columns according to manufacturer’s
protocol (Sigma). The purified product was then ligated using T4 DNA ligase (NEB) at
a 1:5 (vector:insert) molar ratio into NotI/AscI digested pcDNA3.1. Ligated product
was transformed into JM109 competent cells (Promega, Madison, WI, USA) and grown
up on LB + amplicillin plates overnight at 37°C. Colonies were then expanded in LB +
amp selection medium overnight at 37°C, and pellets were subjected to miniprep using
the GenElute Plasmid Miniprep kit (Sigma) according to manufactuer’s protocol. Triple
restriction digest (AscI/NotI/XhoI) was carried out to confirm incorporation of Fyn, and
positive clones were confirmed by sequencing (London Regional Genomics Centre,
Robarts Research Institute, London, Ontario).
Site Directed Mutagenesis
A constitutively active (Fyn Y531F) and dominant negative (Fyn K299M) form
of Fyn kinase were created by site direct mutagenesis. Primers were designed to align
with WT Fyn, replacing the lysine residue at amino acid 299 with a methionine (AAG
 ATG) for FynK299M, and replacing tyrosine 531 with phenalalanine (TAC  TTC)
for Fyn Y531F. Two separate PCR reactions were carried out to create fragment 1 and
fragment 2 of FynK299M using primers listed in table 1 using the generated
pcDNA3.1-hFyn as a template. The reaction was carried out with KOD polymerase
(EMD Biosciences) using the following thermal profile: 95°C for 2 minutes followed by
10 cycles at 94°C for 15 seconds, 60°C (-1°C/cycle) for 15 seconds, and 72°C for 15
seconds, and 25 cycles at 94°C for 15 seconds, 50°C for 15 seconds, and 72°C for 15
seconds. Fragments 1 and 2 were then combined and the full length product was
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generated with KOD polymerase at 95°C for 2 minutes followed by 5 cycles at 94°C for
15 seconds, 60°C (-1°C/cycle) for 15 seconds, and 72°C for 40 seconds. The reaction as
paused to add WT Fyn forward and reverse primers, and the PCR reaction was resumed
with 5 cycles at 94°C for 15 seconds, 55°C (-1°C/cycle) for 15 seconds, and 72°C for
40 seconds, and 25 cycles at 94°C for 15 seconds, 50°C for 15 seconds, and 72°C for 40
seconds. Y531F was generated with a single reaction using KOD polymerase, Y531F
primers listed in table 4.1, and pcDNA3.1-hFyn as a template using the same thermal
profile outlined for cloning WT Fyn.
PCR product from Fyn K299M and Y531F mutagenesis was run on a 1% w/v agarose
gel plus 0.5µg/mL of ethidium bromide (Sigma) to confirm product size.

The

corresponding bands were cut out and extracted with the Sigma GenElute gel extraction
kit according to protocol. A double restriction enzyme digest (NotI/AscI) followed by
digest purification with genElute columns was completed prior to ligation of PCR
product into pcDNA 3.1, transformation into JM109 competent cells, colony expansion
and miniprep as described earlier. Fyn mutant incorporation was confirmed with triple
restriction enzyme digest (AscI/NotI/XhoI), and positive clones were confirmed with
sequencing (London Regional Genomics Centre).
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Table 4.1. Primers used in site-directed mutagenesis
Construct

Forward Primer (5’  3’)

WT Fyn

TAGGCGCGCCAACCATGGG TAGCGGCCGCTTACAGGTTT
CTGTGTGCAATGTAAGGA
TCACCAGGTTGGTACT

Fyn K299M-1

TAGGCGCGCCAACCATGGG GGTTTAAGAGTCATTATGGC
CTGTGTGCAATGTAAGGA
TACTTTTGTGTTTCC

Fyn K299M-2

GTAGCCATAATGACTCTTA
AACCAGGCACAATG
ATGGCGCGCCAACCATGGG
CTGTGTGCAATGTAAGGA

Fyn Y531F

Reverse Primer (5’  3’)

TAGCGGCCGCTTACAGGTTT
TCA
GAGCGGCCGCTTACAGGTTT
TCACCAGGTTGGAACTGGG
GCTC

Transfection
HEK-TRPM2 cells were maintained in DMEM + 10% fetal bovine serum (FBS)
(Invitrogen). Prior to transfection, cells were plated on 100mm dishes at 30%
confluency and induced to express TRPM2 with doxycycline (1µg/mL). The following
day, cells were transfected with JetPRIME™ (Polyplus, Illkirch, France) according to
the manufacturer’s instructions, using 12.5µL instead of the recommended 20-30µL
JetPRIME reagent. After 4 hours, media was replaced with DMEM + 10% FBS +
1µg/mL doxycycline. Cell lysates were collected 48 hours after transfection (lysis
buffer:

150mM NaCl, 0.1% NP-40, 2mM CaCl2, 50mM Tris-HCl (pH 7.5),

supplemented with mini complete protease cocktail inhibitor tablet (Roche) and 1%
Halt phosphatase inhibitor cocktail (Thermo, Rockford, IL, USA). Lysates were
incubated on a nutating shaker for 20 minutes at 4ºC, followed by centrifugation for 30
minutes at 16000 x g at 4ºC. Protein was then quantified from the soluble fraction by
BCA assay (Thermo).
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Immunoprecipitation and Western Blot Analysis
Lysates (1mg protein) were brought up to a volume of 500µL with lysis buffer
plus protease and phosphatase inhibitors and incubated overnight at 4ºC with 20µL
packed monoclonal anti-Flag M2 agarose beads (Sigma). Immunoprecipitates were then
rinsed 3x with 1mL lysis buffer, resuspended in 2x Laemmli sample buffer and heated
for 30 minutes at 37ºC. Samples were subjected to SDS-PAGE on an 8%
polyacrylamide gel and transferred onto a nitrocellulose membrane. Membranes were
cut at 72kDa, and the top portion was probed with an anti-tyrosine antibody (4G10,
1:2000, mouse IgG; Millipore Corp, Billerica, MA) followed by anti-mouse-HRP
secondary antibody (1:5000) and detection with ECL reagent (supersignal, Pierce). The
top portion of the membrane was then stripped and re-probed for TRPM2 using antiFlag-HRP (M2 clone, 1:1000; Sigma) and detected with ECL. The bottom portion of
the gel was probed with an anti-Fyn antibody (H80, 1:500, rabbit igG; Santa Cruz
Biotechnology, Santa Cruz, CA), followed by anti-rabbit-HRP secondary antibody
(1:5000) and detection with ECL reagent. Blots were imaged with the VersaDoc™
imaging system (Biorad).
Statistical Analysis
Data are expressed as mean ± SEM. Statistical analysis was undertaken using
GraphPad Prism® (GraphPad Software, San Diego, CA). An unpaired two-tailed t-test,
one-way ANOVA followed by a Tukey’s HSD post-hoc test, or two-way ANOVA
followed by Bonferroni post-hoc test was used to analyze data. Results were considered
significant when p<0.05.
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4.3 Results
4.3.1 TRPM2 contributes to Aβ toxicity
Our first objective was to examine neuronal viability in response to Aβ
treatment in cultured hippocampal neurons derived from wild type (WT) or TRPM2
knockout (KO) mice. MTT reduction was used to assess cell viability. Cultured
hippocampal neurons at 3 weeks in vitro were treated for 24 hours with 1 µM
oligomeric Aβ. Hippocampal neurons derived from WT cultures demonstrate a decrease
in viability following treatment with Aβ (p<0.05, Figure 4.2). This reduction in viability
is not observed in cultures derived from TRPM2 KO animals (p> 0.05). Importantly, a
scrambled Aβ42 peptide control did not decrease neuronal viability measured by MTT
assay (p>0.05, data not shown). This demonstrate that the genetic deletion of TRPM2
protects hippocampal neurons from the loss of cell viability induced by Aβ oligomers.
4.3.2 Aβ indirectly potentiates TRPM2 currents
We reasoned that the decrease in cell viability occurs as a result of enhanced
TRPM2 currents and increased intracellular Ca2+ levels. To examine this hypothesis,
TRPM2 currents were evoked using in cultured hippocampal pyramidal neurons at 3-4
weeks in vitro following treatment for 24 hour with either 1µM Aβ42 oligomers or
vehicle control. TRPM2 current density was significantly enhanced following pretreatment with Aβ (-17.01 ± 2.13 pA/pF, n=17) relative to vehicle control (-10.64 ±
1.03 pA/pF, n=15, p = 0.015, Figure 4.3A). Interestingly, the same effect is not
observed with HEK293-TRPM2 cells pretreated with 1µM Aβ (-4447 ± 1680 pA, n=6)
compared with vehicle treated controls (-5329 ± 1212 pA, n=7, p=0.67, FIGURE 4.3B),
suggesting that Aβ does not act directly to augment TRPM2 function.
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Figure 4.2. TRPM2 Knockout cultures are protected from Aβ toxicity.
Hippocampal cultures at 3 weeks in vitro were either left untreated, or treated for 24
hours with 1µM oligomerized Aβ1-42. Relative to untreated WT (n=6), and KO (n=7)
cultures, 1µM oligomerized Aβ1-42 significantly reduced viability as measured by MTT
assay in WT cultures, but not in KO cultures (n=8/group). *p<0.05, one-way ANOVA
followed by post-hoc Tukey’s test.
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Figure 4.3. Aβ indirectly potentiates TRPM2 currents
(A) TRPM2 currents were generated in cultured hippocampal neurons at 3-4 weeks in
vitro. Cells were treated for 24 hours with either 1µM oligomerized Aβ1-42 (n = 17) or
vehicle control (n = 15). Currents were normalized to capacitance to control for
variation in cell size. Results demonstrate a current density of -10.64 ± 1.03 pA/pF
(n=15) in control, and -17.01 ± 2.13 pA/pF (n=17) in the Aβ1-42 treated group.
(p=0.015); (B) HEK293-TRPM2 cells were similarly pretreated with either vehicle
control (n=7) or 1µM Aβ1-42 oligomers for 24 hours. Currents were induced with
0.1mM ADPR in the patch pipette. Treatment with Aβ1-42 did not alter TRPM2
amplitude in these cells (p=0.67).
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4.3.1 Fyn Potentiates TRPM2 Currents
A growing body of literature implicates Fyn as a critical player in synaptic
deficits and neurotoxicity associated with Alzheimer’s disease (Yang et al., 2011).
Therefore, we examined whether Fyn could regulate TRPM2 function. Cultured
hippocampal neurons at 3-4 weeks in vitro were used to examine whether currents
elicited from endogenously expressed TRPM2 are enhanced by recombinant Fyn .
Several studies have demonstrated that Fyn regulates NMDARs, enhancing
phosphorylation and activity of the receptor (Salter & Kalia, 2004; Yang, Trepanier et
al., 2011); therefore, in order to exclude any effect of Fyn on the NMDAR, a voltageramp protocol was used to elicit a TRPM2 response. Currents were generated with 0.3
mM ADPR, with or without 1 U/mL Fyn, in the patch pipette. Ramps were applied
either immediately after breakthrough (n=5/group), or after 10 minutes to allow Fyn to
diffuse into the cell (n=3/group). Results from both protocols were combined. As shown
in Figure 4.4A-C, a significant increase in TRPM2 current is observed when Fyn is
delivered via patch pipette in comparison to controls (Fyn, -1087 ± 134.2, N=10;
control, -607.4 ± 121.1, N=9; p<0.05).
HEK 293 cells stably expressing inducible flag-tagged TRPM2 (HEK293TRPM2) used to examine whether inclusion of Fyn (1U/mL) in the patch pipette
directly enhances TRPM2 currents. As shown in figure 4.4D, when compared with
control (-3743 ± 477.8, N=8) recombinant Fyn significantly increased TRPM2 currents
(-5470 ± 425.4, N=8).
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Figure 4.4. Fyn potentiates TRPM2 currents
TRPM2 currents were generated using a voltage ramp protocol in cultured hippocampal
pyramidal neurons with 0.3mM ADPR in the patch pipette. Dashed line indicates
application of 0 Ca2+ ECF. (A) Representative control recording; (B) Representative
Fyn (1U/mL) recording; (C) Compared with controls (-607.4 ± 121.1, N=9), Fyn (1
U/mL, -1087 ± 134.2, N=10) significantly augmented TRPM2 currents; (D) TRPM2
currents were generated in HEK293-TRPM2 cells with 0.1 mM ADPR in the patch
pipette. When compared with controls (-3743 ± 477.8, N=8), Fyn (1 U/mL, -5470 ±
425.4, N=8) significantly potentiates TRPM2 amplitude.
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4.3.2 Fyn Phosphorylates TRPM2
We next examined whether Fyn promotes TRPM2 tyrosine phosphorylation in
HEK293-TRPM2 cells transfected with various Fyn constructs. Fyn kinase was cloned
into a pcDNA3.1 vector and site directed mutagenesis was used to produce a
consitutively active form of Fyn kinase (Fyn Y531F) as well as an inactive Fyn kinase
(Fyn K299M). These forms of Fyn have been previously described and characterized
(Maulon et al., 2001; Twamley et al., 1992). HEK293-TRPM2 cells were transfected
with these constructs or empty vector control, and induced to express TRPM2. TRPM2
was immunoprecipitated, run by SDS-PAGE, and probed for tyrosine phosphorylation
(Figure 4.5). Results demonstrate that there is a significant difference between groups
(p= 0.0124), with constitutively active Fyn enhancing TRPM2 tyrosine phosphorylation
by approximately 6-fold over WT Fyn (p <0.05, one-way ANOVA followed by posthoc Tukey’s test).

4.3.3 Fyn Co-Immunoprecipitates with TRPM2
To examine whether Fyn interacts with TRPM2, TRPM2 pull-downs from
HEK293-TRPM2 cells transfected with the various Fyn constructs were run by SDSPAGE and probed for Fyn. Indeed, Fyn interacts with TRPM2.

Interestingly, a

significant difference between groups was observed (p = 0.009), with an enhanced
interaction observed with the Fyn Y531F constitutively active mutant relative to WT
(Figure 4.6A,B, p < 0.05). No significant difference between Y531F and WT Fyn input
was observed (data not shown), suggesting that the interaction between Fyn and
TRPM2 is enhanced when Fyn kinase is active.
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Figure 4.5. TRPM2 tyrosine phosphorylation by Fyn.
HEK293-TRPM2 cells were transfected with empty vector (EV), wildtype Fyn (WT),
constitutively active Fyn (Y531F), or inactive Fyn (K299M). Flag-tagged TRPM2
channels were immunoprecipitated from protein lysates and probed for tyrosine
phosphorylation, and were subsequently striped and re-probed for TRPM2. Normalized
values (pY TRPM2 / total TRPM2) were compared between groups (n=4 per
treatment). (A) Representative blot. (B) A significant increase in tyrosine
phosphorylation of TRPM2 is observed when co-transfected with constitutively active
Fyn. Results are analyzed by one-way ANOVA followed by post-hoc Tukey’s test.
Identical letters at top of bars indicate no significant difference between groups
(p>0.05).
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Figure 4.6. TRPM2 Interacts with Fyn
In 4 separate experiments, HEK293-TRPM2 cells were transfected with empty vector
(EV), wildtype Fyn (WT), constitutively active Fyn (Y531F), or inactive Fyn (K299M).
Flag-tagged TRPM2 channels were immunoprecipitated from protein lysates, and
immunoprecipitates were then run by SDS-PAGE, transferred to a nitrocellulose
membrane, and probed for Fyn. To control for variations in TRPM2 expression and
pull-down, the Fyn signal was normalized to flag-TRPM2 (A) Representative blot. (B)
Fyn was co-immunoprecipitated with TRPM2 irrespective of the Fyn variant used. A
significant increase in pull-down was observed with constitutively active Fyn (Y531F)
relative to all other groups. Results are analyzed by one-way ANOVA followed by posthoc Tukey’s test. Identical letters at top of bars indicate no significant difference
between groups (p>0.05).
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4.3.4 Fyn(39-57) Peptide Attenuates TRPM2 Currents
Our current results suggest that Fyn is an important regulator of TRPM2. We
therefore wanted to examine whether a peptide developed against the unique domain of
Fyn could inhibit TRPM2 currents. This peptide corresponds to Fyn amino acids 39-57,
and is proposed to disrupt interactions between Fyn and target or scaffolding proteins
((Yang, Trepanier et al., 2011). As shown in Figure 4.7, TRPM2 currents of -692.0166
+/- 88.57842 pA in amplitude are elicited in control conditions in cultured hippocampal
neurons (n=12) after 25 minutes of recording; however, inclusion of the Fyn(39-57)
peptide (25 ng/mL in the patch pipette) significantly diminished the TRPM2 response (224.2 +/- 24.2 pA, n=9).
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Figure 4.7. Fyn(39-57) peptide attenuates TRPM2 in hippocampal neurons
Cultured hippocampal neurons at 3-4 weeks in vitro were used to assess the effect of a
the Fyn(39-57) mimetic peptide. In the absence of ADPR, repeated applications of
NMDA activates TRPM2 and enhances the holding current to -692.0166 +/- 88.57842
pA after 25 minutes (Fyn CTL, n=12). Inclusion of the Fyn(39-57) peptide (25 ng/mL)
in the patch pipette significantly attenuates the TRPM2 response, resulting in a current
of -224.2 +/- 24.2 pA after 25 minutes (Fyn I, n=9).
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4.4 Discussion
In this study, we demonstrate a role for TRPM2 in Aβ mediated cell death, and
also examined the physical and functional link between Fyn kinase and TRPM2
channels. We employed cultured hippocampal neurons to demonstrate that the genetic
deletion of TRPM2 attenuates the decrease in cell viability induced by a 24 hour
treatment with 1µM oligomeric Aβ. One study had previously concluded that a
dominant negative form of TRPM2 and knock-down of TRPM2 can protect against Aβmediated cell death (Fonfria et al., 2005). Importantly, this preliminary finding was
investigated using 20 µM Aβ in striatal cultures; however, degeneration in Alzheimer’s
disease occurs within the basal forebrain cholinergic neurons, entorhinal cortex,
hippocampus, and cortex (Coyle et al., 1983; Gomez-Isla et al., 1996)(Coyle et al.,
1983; Gomez-Isla et al., 1996), and it is the oligomeric, not monomeric, form of Aβ that
has been shown to induce an influx of intracellular calcium, significantly increase
oxidative stress, and be particularly toxic to neurons (De Felice et al., 2007; Demuro et
al., 2005; Lambert et al., 1998). The use of hippocampal cultures, along with use of
oligomeric Aβ used in this study more accurately reflects the pathological conditions
associated with Alzheimer’s disease, and implicates the channel in the disease process.
Subsequent studies should be designed to assess whether genetic deletion of TRPM2
can modify morbidity or mortality in transgenic models of Alzheimer’s disease.
Following exposure to Aβ oligomers, TRPM2 currents are enhanced in cultured
hippocapal neurons. This increase in current cannot be recapitulated in HEK cells
expressing the TRPM2 channel. This suggests that Aβ enhances TRPM2 currents
through an indirect mechanism. We hypothesize that the pathway will include Fyn
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kinase. Therefore, we examined whether Fyn kinase could regulate the TRPM2 channel.
In cultured hippocampal pyramidal neurons, we demonstrate that inclusion of Fyn
kinase in the patch pipette increases TRPM2 current density when compared with
controls. In addition, we used HEK293-TRPM2 cells transfected with empty vector or
various forms of Fyn to demonstrate that TRPM2 is tyrosine phosphorylated by Fyn
kinase, and this phosphorylation is significantly enhanced with constitutively active Fyn
relative to WT Fyn. Furthermore, we demonstrate that Fyn interacts with TRPM2, and
this interaction may be increased when Fyn is active. A peptide which mimics the
unique domain of Fyn disrupts TRPM2 activation in cultured hippocampal pyramidal
neurons.
Further experiments are required to assess whether Fyn is involved in the
potentiation of TRPM2 currents by Aβ. Furthermore, it is unclear whether the
interaction between Fyn and TRPM2 is direct or through a separate scaffolding protein.
Analysis of the structure of TRPM2 reveals several proline rich motifs (PxxP), which
could be involved in binding to the SH3-domain of Fyn kinase. These motifs are located
in both the N- and C- terminal portions of TRPM2 at amino acids 544-547, 551-554,
575-578, 1078-1081, 1248-1251, and 1324-1327. Deletion of one of both of the Nterminal PxxP motif at 544-547 and 551-554 does not alter activation of TRPM2 by
ADPR or H2O2 (Kuhn et al., 2009). Whether any PxxP motifs in TRPM2 participate in
the interaction between Fyn and TRPM2 has not been investigated. Further research is
also required to identify tyrosine phosphorylation sites on TRPM2 targeted by Fyn. The
predictive software programs GPS 2.1 and PhosphoNet online application identify 10
putative sites on TRPM2 which may be phosphorylated by Fyn. These sites are Y74,
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Y142, Y523, Y682, Y1127, Y1132, Y1271, Y1301, Y1349 and Y1503. Studies are
currently in progress to identify the site(s) on TRPM2 which are phosphorylated by
Fyn.
Our current results show the importance of continuing studies to determine the
pathway through which TRPM2 currents are augmented by Aβ. Whether Fyn
participates in this effect remains to be elucidated. A more complete understanding of
this pathway may help to identify whether TRPM2 or the interaction between Fyn and
TRPM2 could represent a potential target for development of novel therapeutics in AD.
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5. Discussion
TRPM2 is a Ca2+ permeable channel activated by oxidative stress which has also been
tightly linked to cell death (Takahashi et al., 2011). The highest level of TRPM2
expression is observed in the brain, where TRPM2 is expressed in several cell types
including pyramidal neurons of the hippocampus (Fonfria et al., 2006; Olah et al.,
2009). The purpose of this PhD thesis was to determine the physiological role of
TRPM2 in these neurons, and elucidate novel pathways which regulate channel
expression or function. A combination of electrophysiology and molecular biology
approaches in cultured cell lines, primary hippocampal cultures, and hippocampal slice
preparations were employed. Results presented in this thesis demonstrate that: (1)
TRPM2 participates in NMDAR-dependent LTD by regulating GSK-3β activity, as
well as expression of AMPAR and PSD-95 (Xie et al., 2011); (2) TRPM2 activity is
enhanced in cultured hippocampal neurons over time in vitro due to the loss of tonic
inhibition by GSH (Belrose et al., 2012); (3) TRPM2 plays a role in Aβ toxicity,
potentially through a pathway involving Fyn, a tyrosine kinase which regulates TRPM2
in an activity dependent manner. This section will address the significance and
implications of these findings.

5.1 TRPM2 Participates in Synaptic Plasticity
This thesis was the first to characterize the physiological role for TRPM2 in
hippocampal pyramidal neurons. Employing TRPM2 knockout (KO) mice allowed us
to validate the functional expression of TRPM2 in hippocampal pyramidal neurons. We
determined that TRPM2 contributes to NMDAR-dependent LTD at hippocampal CA3-
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CA1 synapses. The absence of TRPM2 does not alter NMDAR currents or NMDAR
subunit composition. Similarly, no change in VDCC currents is observed in cultured
hippocampal pyramidal neurons from KO animals relative to WT control. Instead, the
loss of NMDAR-dependent LTD in KO hippocampal slices results from increased
inactivation of GSK-3β, and a reduction in the expression of PSD-95 and AMPARs.
The loss of NMDAR-LTD could be recapitulated with the TRPM2 antagonist
clotrimazole, demonstrating that the observed changes in synaptic plasticity were not
due to developmental changes induced by genetic deletion of TRPM2. Furthermore,
increasing the activity of GSK-3β by treatment with quinpirole, a D2 receptor agonist,
rescued LTD induction.
The signaling pathway through which TRPM2 regulates GSK-3β activity is
likely to involve Ca2+. The increase in Ser9 phosphorylation in KO animals could
suggest a decrease in activity of a Ca2+-dependent phosphatase. Calcineurin (also
known as PP2B), a phosphatase regulated by Ca2+, dephosphorylates GSK-3β at Ser9,
and could mediate the change in GSK-3β activation downstream of TRPM2 (Y. Kim et
al., 2009). Whether calcineurin activity is decreased in KO hippocampal tissue has not
yet been assessed.
The decrease in AMPAR and PSD-95 expression in KO hippocampal slices also
requires further exploration. This result, combined with a reduced AMPA/NMDA ratio,
and a diminished mEPSC amplitude in KO slices, suggests that the contribution of
AMPAR to excitatory synaptic transmission is reduced when TRPM2 is absent. The
current study used total hippocampal lysates to assess AMPAR and PSD-95 expression.
Whether the reduction in AMPAR is synapse specific, extrasynaptic, or was uniform
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across the cell was not assessed. We demonstrated that clotrimazole could inhibit
NMDAR-dependent LTD. Whether this treatment also produced a reduction in PSD-95
and AMPAR, or whether the loss of expression is due to a prolonged loss of TRPM2 or
development changes due to genetic deletion of TRPM2 was not investigated. Lastly,
the mechanism responsible for reduced AMPAR and PSD-95 expression was not
explored. Whether a change in AMPAR and PSD-95 is due to a reduced transcription,
translation, trafficking to the cell membrane, or enhanced degradation, should be
explored to identify potential pathways through which TRPM2 may be regulating
AMPAR and PSD-95 expression.
The behavioural consequences resulting from the genetic deletion of TRPM2 is
still under investigation. Preliminary results in our lab have shown that TRPM2 KO
mice perform the same as their WT controls on tests of locomotion, anxiety, and spatial
learning. Specifically, no differences are observed between WT and KO animals at 9
months of age on the open field, elevated plus maze, Barnes maze, or object recognition
tasks (M. Chen et al., unpublished). The absence of NMDAR-dependent LTD provides
some insight into which behavioural tasks should be examined next in TRPM2 KO
animals relative to controls. Specifically, the absence of LTD has been shown to impair
behavioural flexibility, which can be evaluated by reversal learning in the Morris water
maze and by the delayed non-match to place T-maze task (J. I. Kim et al., 2011).
Identification of the physiological role of TRPM2 in hippocampal pyramidal
neurons not only contributes to the characterization of the TRPM2 channel, but it also
furthers our understanding of the cellular mechanisms underlying learning and memory.
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Furthermore, it allows us to identify potential consequences of directly inhibiting
TRPM2 in a clinical setting.

5.2 TRPM2 Activity and Aging
TRPM2 currents are enhanced in cultured hippocampal neurons over time in
vitro. The functional increase in TRPM2 currents is attributed to depletion of GSH with
age, and the loss of tonic inhibition of the channel by GSH. Contrary to the previously
proposed mechanisms of TRPM2 inhibition by GSH, inhibition is not due to the
reducing effects of GSH. Inhibition by GSH is also independent of protein interactions
with the cysteine residue in GSH since the effects of GSH can be recapitulated with
ophthalmic acid, an analogue with an aminobutyrate group replacing the cysteine
residue. The interaction between GSH and TRPM2 may play an important role in aging
and neurological diseases associated with depletion of GSH.
A shift in the concentration-response curve shows that GSH produces a 3.5fold
inhibition of the TRPM2 response to the intracellular agonist, ADPR. Interestingly,
preliminary evidence suggests that ADPR may enhance the interaction between GSH
and TRPM2 (J. Belrose, unpublished). Rather than GSH competing for the ADPR
binding site on TRPM2, this result raises the possibility that GSH may function by
binding to ADPR and disrupting proper channel activation. In support of this idea, a
previous publication demonstrated that GSH covalently binds to ribose through an
interaction between the glutamyl group of GSH and the aldehyde group of ribose
(Januel et al., 2003). Whether this reaction also occurs between GSH and ADPR has not
yet been assessed.
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To determine whether TRPM2 currents are also elevated with age in vivo,
TRPM2 currents can be recorded from aged WT hippocampal slices. As mentioned
previously, no TRPM2 KO phenotype has been identified out to 9 months of age on the
open field, elevated plus maze, object recognition, or Barnes Maze (M. Chen,
unpublished). The results presented in this thesis suggest that a behavioural phenotype
may be more apparent in aged mice.
In addition to normal aging, GSH is also reduced in Parkinson’s disease (Martin
& Teismann, 2009). TRPM2 is expressed and functional in dopaminergic neurons of the
substantia nigra affected by Parkinson’s disease (Chung, Freestone, & Lipski, 2011).
Most Parkinson’s disease cases are sporadic, with familial Parkinson’s accounting for
less than 15% of cases. Transgenic mouse models targeting the various genes
implicated in familial Parkinson’s disease have not yet produced a model that displays
nigrostriatal neuronal degeneration (Blandini & Armentero, 2012). The 1-methyl 4phenyltetrahydropyridine (MPTP) systemic neurotoxin model of Parkinson’s disease,
however, is selectively toxic to the dopaminergic neurons in the nigrostriatal pathway
within one week following injection (Blandini & Armentero, 2012). To examine
whether TRPM2 is implicated in Parkinson’s disease, TRPM2 WT and KO animals
could be assessed for performance on a grid-walking test and treadmill activity
immediately prior to and two weeks following injection of vehicle control or MPTP.
In addition to GSH depletion in Parkinson’s disease, GSH is also reduced in
progressive supranuclear palsy, bipolar disorder, major depressive disorder, and
schizophrenia (Martin & Teismann, 2009; Perry, Godin, & Hansen, 1982; Sian et al.,
1994)(Anderson & Sims, 2002; Bragin et al., 2010; Rehncrona & Siesjo, 1979; Salemi
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et al., 2009)(Do et al., 2000; Gawryluk et al., 2011). Several studies have linked SNPs
in TRPM2 to bipolar disorder (Kostyrko et al., 2006; McQuillin et al., 2006; Xu et al.,
2006; Xu et al., 2009). Whether the other neurodegenerative and neuropsychiatric
disorders associated with GSH depletion demonstrate SNPs in TRPM2 has not yet been
investigated.

5.3 Potential Implications to Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting
memory, orientation, and reasoning. In Canada, the disease is estimated to affect 1.5%
of our total population (Alzheimer Society of Canada, 2010).
Soluble oligomers of Aβ initiates a toxic cascade, resulting in the pathological
modification of tau, and subsequent targeting of Fyn kinase to NMDARs (Ittner et al.,
2010). The interaction between Fyn and tau is disrupted in tau -/-and tau74 mice
(transgenic mice which express only the N-terminal projection domain of tau),
decreasing the targeting of Fyn to the synapse. A reduction in mortality and cognitive
deficits in an AD mouse model (APP23) are observed when these mice are crossed with
tau -/- or tau74 mice. The Tat-NR2B9c peptide, a peptide which disrupts the interaction
between NMDAR subunit 2B (GluN2B) and PSD-95, similarly rescued the memory
deficits and lethality in APP23 mice (Ittner et al., 2010).
In agreement with the finding that Fyn is instrumental in AD, behavioural
deficits and neurotoxicity in an AD mouse model can be enhanced with overexpression
of Fyn (Chin et al., 2004; Chin et al., 2005). Similarly, hippocampal slices from Fyn
knockout mice are protected from cell death induced by soluble oligomeric Aβ
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(Lambert et al., 1998). In contrast, in the triple transgenic (3xTg) model of Alzheimer’s
disease, 3xTg(+/-) mice exhibit augmented spatial learning deficits and Aβ
accumulation

when

Fyn

is

knocked

down

(Fyn+/-)

relative

to

controls

(Fyn(+/+)3xTg(+/-)) (Minami et al., 2012). This last result is not surprising when one
considers the role for Fyn in LTP induction (Grant et al., 1992; Kojima et al., 1997).
Furthermore, Fyn plays a critical role in oligodendrocyte production and subsequent
neuronal myelination (Kramer-Albers & White, 2011; Osterhout et al., 1999). A
conditional knockout of Fyn kinase in an AD mouse model would help to clarify
whether the enhanced deficits in the 3xTg(+/-) mice are a result of developmental
changes, or whether the effect can also be recapitulated when Fyn is knocked out after
disease onset. Until this phenomenon has been explored further, the study by Minami
and colleagues (2012) raises the possibility that global inhibition of Fyn may not
provide therapeutic benefit to individuals diagnosed with AD. Further research into
pathways altered by Fyn may uncover a more targeted approach for pharmacological
intervention in AD.
As discussed previously, the toxic triad of tau, Fyn, and NMDARs are unlikely
to explain all of the neurotoxicity and synaptic deficits observed in AD. Here, we
propose that TRPM2 may participate in this protein complex. First, we demonstrate that
TRPM2 plays a role in decreasing synaptic strength, a hallmark of AD (Xie et al.,
2011). We further demonstrate that currents are enhanced by glutathione depletion over
time in vitro, raising the possibility that glutathione depletion with age in vivo may
produce an age-dependent increase in TRPM2 currents (Belrose et al., 2012). In chapter
4, we demonstrated that genetic deletion of TRPM2 protects against the reduction in
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cell viability associated with oligomeric Aβ treatment. Furthermore, we demonstrated
that TRPM2 currents are indirectly enhanced by Aβ, and that the channel is regulated
by Fyn, an important player in AD (Belrose, Johnson, Li, Caetano, MacDonald &
Jackson, unpublished).
A future direction of this project will examine the hypothesis that knockout of
TRPM2 will protect against memory deficits and mortality in a mouse model of
Alzheimer’s disease. To examine whether knockout of TRPM2 also protects against
mortality and cognitive deficits in an Alzheimer’s disease mouse model, we have
crossed TRPM2+/- mice with APPswePS1dE9 transgenic mice. This model of
Alzheimer’s disease co-expresses the swedish mutation of APP with a presinilin (PS1)
lacking exon 9 (Jankowsky et al., 2004; Malm, Koistinaho, & Kanninen, 2011; Xiong et
al., 2011) Four genotypes (TRPM2+AD-, TRPM2-AD-, TRPM2+AD+, AND TRPM2AD+) will be tested on the open field, elevated plus maze, object recognition, Barnes
maze, and Morris Water Maze to assess for changes in locomotion, anxiety, and
memory. In APPswePS1dE9 mice, memory deficits on the Morris water maze appear at
12 months of age (Xiong et al., 2011). We propose that the deficits observed in the
TRPM2+AD+ will be attenuated in the TRPM2-AD+.
We also hypothesize that the enhancement of TRPM2 currents by Aβ oligomers
involves Fyn kinase. To examine this hypothesis, shRNA targeting Fyn will be used to
knock-down expression of Fyn. A lentiviral system will be used to infect cultured
hippocampal neurons with Fyn shRNA or scrambled shRNA control. In addition to
allowing expression of shRNA driven by a U6 promoter, the transfer vector (pLB) used
also allows expression of GFP with expression driven by a CMV promoter. Infection
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rates in excess of 80% have routinely been achieved in our cultured hippocampal
neurons. If Fyn is involved in potentiation of TRPM2 current by Aβ, we anticipate that
knockdown of Fyn kinase would attenuate Aβ-mediated enhancement of TRPM2
currents in cultured neurons relative to scrambled shRNA infected controls.

5.4 Regulation of TRPM2 by Fyn
Fyn interacts with and phosphorylates TRPM2, and enhances TRPM2 currents.
This is the first study to identify a kinase which acts upon TRPM2, and represents a
novel regulatory mechanism which may play an important role in oxidative stress and
Alzheimer’s disease. It is unclear whether the interaction between Fyn and TRPM2 is
direct or through a separate scaffolding protein. Analysis of the structure of TRPM2
reveals several proline rich motifs (PxxP), which could be involved in binding to the
SH3-domain of Fyn kinase. Whether any PxxP motifs in TRPM2 participate in the
interaction between Fyn and TRPM2 has not been investigated. Alternatively, Fyn may
interact with TRPM2 through an intermediate protein such as a scaffolding protein. The
precise nature of the interaction between TRPM2 and Fyn requires further exploration,
and may lead to the development of a more specific inhibitory peptide.
The current study used intracellular applications of recombinant Fyn kinase to
assess the effect on TRPM2 currents. We demonstrated that acute Fyn kinase enhanced
TRPM2 current amplitude; however, it is unclear whether a more chronic exposure to
activated Fyn would produce the same effect. Results from western blotting
experiments raise the possibility that Fyn exerts a dichotomous effect on TRPM2:
acutely enhancing currents, and reducing TRPM2 expression in more chronic
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conditions. Total cell lysate from HEK293-TRPM2 cells transfected with the various
Fyn constructs were separated by SDS-PAGE to assess TRPM2 and Fyn expression. To
our surprise, we consistently observed a decrease in TRPM2 expression normalized to
β-actin when constitutively active Fyn was transfected (Figure 5.1). Importantly, no
change in β-actin levels was observed between groups (p>0.05). This decline in TRPM2
expression may represent a difference in protein production, trafficking, endocytosis
and degradation, or cell proliferation and viability. If cells expressing TRPM2 have
diminished proliferation, or undergo apoptosis or necrosis in response to overexpression
of constitutively active Fyn, we would expect a decrease in total protein levels in lysates
collected from these cells. Analysis of protein concentration reveals that there is no
difference in protein levels between the groups (one way ANOVA, p = 0.68, data not
shown). Further research is needed to first assess whether surface expression of TRPM2
is altered, and subsequently to assess whether a change in protein production,
trafficking, endocytosis, or degradation underlies the reduction of TRPM2 in response
to constitutively active Fyn. This result also raises the intriguing possibility that,
although acute Fyn enhances TRPM2 currents, chronically active Fyn may decrease
TRPM2 activity through a reduction in TRPM2 expression.
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Figure 5.1. Constitutively active Fyn decreases TRPM2 expression.
Total protein from HEK-TRPM2 cells transfected with EV, WT, constitutively active
(Y531F), or inactive (K299M) Fyn were separated by SDS-PAGE and analyzed for
flag-TRPM2 and Fyn input, normalized to β-actin expression. (A) Representative blots;
(B) TRPM2 input normalized to β-actin demonstrates a significant reduction in TRPM2
expression relative to empty vector (n=4/treatment) (C) Fyn input normalized to β-actin
demonstrates expression of Fyn with transfection of each construct. A significant
reduction in Fyn expression is observed with K299M relative to Y531F; however,
neither construct exhibit a significant change in expression relative to WT Fyn (n=4).
Results are analyzed by one-way ANOVA followed by post-hoc Tukey’s test. Identical
letters at top of bars indicate no significant difference between groups (p>0.05).
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Interestingly, TRPM7, another member of the TRPM subfamily of cation
channels, may be regulated by Src kinase, a related kinase with significant homology to
Fyn (Jiang, Newell, & Schlichter, 2003). Similar to the inhibition of TRPM2 by
Fyn(39-57), TRPM7 currents are inhibited with Src(40-58) in microglia (Jiang et al.,
2003). Considering the similarity between TRPM2 and TRPM7, as well as the
homology between Fyn and Src kinase, we wondered whether Src kinase may also
regulate TRPM2 channels. In HEK293-TRPM2 cells, we demonstrate that recombinant
Src (1U/mL) in the patch pipette significantly potentiates TRPM2 currents (-6193 ±
505.1, N=10) relative to controls (-4831 ± 213.9, N=7) as shown in Figure 5.2.
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Figure 5.2. Src potentiates TRPM2 currents
TRPM2 currents were generated in HEK293-TRPM2 cells with 0.1 mM ADPR in the
patch pipette. When compared with controls (-4831 ± 213.9, N=7), Src (1 U/mL, -6193
± 505.1 N=10) significantly potentiates TRPM2 amplitude
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5.5 Conclusion
Our lab previously demonstrated that TRPM2 is expressed and functional in
hippocampal pyramidal neurons; however, the physiological role and various pathways
regulating TRPM2 had not yet been established (Olah et al., 2009). Substantial evidence
demonstrates that TRPM2 plays an important role in cell death (Takahashi et al., 2011).
Here, we identified that TRPM2 is required for NMDAR-dependent LTD through the
regulation of GSK-3β activity (Xie et al., 2011). We examined TRPM2 currents over
time in vitro and provide evidence that TRPM2 currents are enhanced with GSH
depletion (Belrose et al., 2012). This raises the possibility that TRPM2 currents may be
enhanced with normal aging and in the various neurodegenerative and psychiatric
disorders associated with GSH depletion. Furthermore, we demonstrate that cultured
hippocampal neurons derived from TRPM2 KO mice show an attenuated loss of cell
viability following treatment with Aβ oligomers when compared with WT cultures. We
also demonstrate that Fyn kinase is capable of interacting with, and phosphorylating
TRPM2. Delivery of recombinant Fyn through the patch pipette potentiates TRPM2
currents. Combined, this data raises the possibility that TRPM2 may play a role in
Alzheimer’s disease pathology (Figure 5.3)
Elucidating the properties and physiological role(s) of TRPM2 is still in the
early stages; however, these findings open the door to several subsequent studies on the
significance of TRPM2 to normal function and potential contribution to various
neurological diseases.
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Figure 5.3 Summary
In addition to a role for TRPM2 in cell death, the channel also participates in decreasing
synaptic strength via regulation of GSK-3β activity. TRPM2 is tonically inhibited by
GSH which can be depleted with age. Furthermore, the channel is activated by Fyn, a
Src-family kinase implicated in Alzheimer’s disease. Treatment with Aβ, the initiating
factor of Alzheimer’s pathogenesis, enhances TRPM2 currents through an unknown
mechanism. This may involve Fyn kinase since treatment with Aβ results in the
downstream hyperphosphorylation of tau via several kinases including GSK-3β, and the
mislocalization of Fyn in response to pathologically modified tau.
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You agree that we may publish your article, and that we may sell or distribute it, on its
own, or with other related material.
By submitting your article for publication to one of our publications, you promise that
the article is your original work, has not previously been published, and is not currently
under consideration by another publication. You also promise that the article does not,
to the best of your knowledge, contain anything that is libellous, illegal or infringes
anyone’s copyright or other rights. If the article contains material that is someone else’s
copyright, you promise that you have obtained the unrestricted permission of the
copyright owner to use the material and that the material is clearly identified and
acknowledged in the text.
We promise that we will respect your rights as the author(s). That is, we will make sure
that your name(s) is/are always clearly associated with the article and, while you do
allow us to make necessary editorial changes, we will not make any substantial
alterations to your article without consulting you.
Copyright remains yours, and we will acknowledge this in the copyright line that
appears on your article. You also retain the right to use your own article (provided you
acknowledge the published original in standard bibliographic citation form) in the
following ways, as long as you do not sell it in ways that would conflict directly with
our efforts to disseminate it.
1. You are free to use the manuscript version of your article for internal,
educational or other purposes of your own institution or company;
2. You may use the article, in whole or in part, as the basis for your own
further publications or spoken presentations;
3. For a fee of €100, you will have the right to mount the final version of your
article as published by IOS Press on your own, your institution’s, company’s or
funding agency’s website. You can order this right together with the final
published version of your article with the form sent to the corresponding author
along with the proofs of your paper.
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BioMed Central copyright and license agreement
In submitting a research article ('article') to any of the journals published by BioMed
Central Ltd ('BioMed Central') I certify that:
1. I am authorized by my co-authors to enter into these arrangements.
2. I warrant, on behalf of myself and my co-authors, that:
a. the article is original, has not been formally published in any other peer-reviewed
journal, is not under consideration by any other journal and does not infringe any
existing copyright or any other third party rights;
b. I am/we are the sole author(s) of the article and have full authority to enter into this
agreement and in granting rights to BioMed Central are not in breach of any other
obligation. If the law requires that the article be published in the public domain,
I/we will notify BioMed Central at the time of submission upon which clauses 3
through 6 inclusive do not apply;
c. the article contains nothing that is unlawful, libellous, or which would, if published,
constitute a breach of contract or of confidence or of commitment given to secrecy;
d. I/we have taken due care to ensure the integrity of the article. To my/our - and
currently accepted scientific - knowledge all statements contained in it purporting to
be facts are true and any formula or instruction contained in the article will not, if
followed accurately, cause any injury, illness or damage to the user.
And I agree to the following license agreement:
BioMed Central Open Access license agreement
Brief summary of the agreement
Anyone is free:
•
to copy, distribute, and display the work;
•
to make derivative works;
•
to make commercial use of the work;
Under the following conditions: Attribution
•
the original author must be given credit;
•
for any reuse or distribution, it must be made clear to others what the license
terms of this work are;
•
any of these conditions can be waived if the authors gives permission.
Statutory fair use and other rights are in no way affected by the above.
Full BioMed Central Open Access license agreement
(Identical to the 'Creative Commons Attribution License')

173

ANIMAL USE PROTOCOL
January 29, 2009
*This is the Original Approval for this protocol*
*A Full Protocol submission will be required in 2013*

Dear Dr. Macdonald and Dr. Jackson:

Your Animal Use Protocol form entitled: Non-Selective Cation Channels in Stroke
Funding Agency CHR -Grant #MOP-15514
has been approved by the University Council on Animal Care. This approval is valid from January 29, 2009
to January 31, 2010. The protocol number for this project is 2009-002.
1. This number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this number.
3. If no number appears please contact this office when grant approval is received. If the application for
funding is not successful and you wish to proceed with the project, request that an internal scientific peer
review be performed by the Animal Use Subcommittee office.
4. Purchases of animals other than through this system must be cleared through the ACVS office. Health
certificates will be required.
ANIMALS APPROVED FOR 4 Years
Species
Mouse
Rat
Mouse
Mouse
Mouse
Mouse

Strain
Swiss
Wistar
NR2A KO
NR2A KO
TRPM2 KO
TRPM2 KO

Other Detail
Pregnant females
2 week ‐adults
2 week ‐adults
adult breeders M/F
2 week ‐adults
adult breeders M/F

Pain Level

C
C
C
C
C
C

Animal # Total for 4 Years
800
5200
600
40
1600
40

REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this
protocol, are familiar with the contents of this document
c.c. Approved Protocol - J. MacDonald, M. Jackson, W. Lagerwerf, M. Pickering
Approval Letter - J. MacDonald, M. Jackson, W. Lagerwerf, M. Pickering

The University of Western Ontario
Animal Use Subcommittee / University Council on Animal Care
Health Sciences Centre, ● London, Ontario ● CANADA – N6A 5C1
PH: 519-661-2111 ext. 86770 ● FL 519-661-2028 ● www.uwo.ca / animal
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Curriculum Vitae

EDUCATION
In Progress

MD/PhD candidate – University of Western Ontario
Anatomy & Cell Biology
Supervisor: Dr. John MacDonald
Thesis topic: TRPM2 in the CNS: Physiological role and critical
regulatory pathways

2009

MSc – McMaster University
Medical Sciences
Supervisor: Dr. Margaret Fahnestock
Thesis topic: Mechanism of brain derived neurotrophic factor
(BDNF) dysregulation in Alzheimer’s disease and related
tauopathies

2007

BHSc (honours) – McMaster University
Bachelor of Health Sciences
Supervisor: Dr. Laurie Doering
Thesis topic: Fragile-X Mental Retardation Protein (FMRP)
Expression in Astrocytes

AWARDS & HONOURS
2012

Canadian Society for Clinical Investigation (CSCI) Young Investigators
Forum Poster Award (neuroscience)
Value: $100

2012

Suzanne M. Bernier Publication Award
Publication Award – Department of Anatomy & Cell Biology
Value: $150

2012

London Health Research Day
Poster Award – Neuroscience and Mental Health
Value: $500

175

2011

A.C. Camargo Global Meeting of Translational Science
Travel Award
One of 50 international candidates selected to attend the course
“Molecular Medicine: From Bench to Bedside” in Sao Paulo, Brazil
Value: Full coverage of travel costs (hotel, transportation, meals)

2010

Canadian Society for Clinical Investigation (CSCI) Young Investigators
Forum Poster Award (neuroscience)
Value: $75 + one year associate membership with CSCI

2009 - 2015

CIHR – MD/PhD Program Grant
Awarded to the top ranked incoming MD/PhD student
Value: $132,000

2009

NSERC – PGS (D3) - declined
Value: $63,000

2009 - 2012

University of Western Ontario – Schulich Graduate Scholarship
Value: ~ $7000/year (tuition stipend)

2009

NSERC – Michael Smith Foreign Study Supplement (MFSS) - declined
Value: $4,360

2008

NSERC – CGS (M) Alexander Graham Bell Scholarship
Value: $17,500

2008

McMaster Medical Sciences Scholarship
Value: $5,000

2007

Ontario Graduate Scholarship (OGS)
Value: $15,000

PUBLICATIONS/PRESENTATIONS
PUBLICATIONS
Appleton, T.*, Belrose, J.C.*, Ward, M., & Young, F. (submitted, Clinical and
Investigative Medicine). Strength in numbers: Growth of Canadian clinician investigator
training in the 21st century. *these authors contributed equally to this work
Jamshidi, F., Schmidt, A., & Belrose, J.C. (submitted, Clinical and Investigative
Medicine). Scientific overview: CSCI-CITAC annual general meeting and young
investigators forum 2011.
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MacDonald, J.F., Belrose, J.C., Xie, Y.F., & Jackson, M.F. (2013). Nonselective ion
channels and links to hippocampal ischemia, aging, and dementia. Adv. Exp. Med. Biol.
961: 433-447.
Belrose, J.C., Xie, Y.F., Gierszewski, L.J., MacDonald, J.F., & Jackson, M.F. (2012).
Loss of glutathione homeostasis associated with neuronal senescence facilitates TRPM2
channel activation in cultured hippocampal pyramidal neurons. Molecular Brain, 5:11.
Belrose, J.C., Caetano, F., Yang, K., Lockhart, B.M.W., Jackson, M.F., & MacDonald,
J.F. (2012). Mechanisms of calcium influx following stroke. In Li, Y.V. & Zhang, J.H
(Eds), Metal Ion in Stroke. New York, NY: Springer. (ISBN 978-1-4419-9662-6)
Xie, Y.F.*, Belrose, J.C.*, Tymianski, M., Mori, Y., MacDonald, J.F., Jackson, M.F.
(2011). Dependence of NMDA/GSK3β mediated metaplasticity on TRPM2 channels at
hippocampal CA3-CA1 synapses. Molecular Brain, 4:44. *these authors contributed
equally to this work
Yang, K.*, Belrose, J.*, Trepanier, C.H., Lei, G., Jackson, M.F., & MacDonald, J.F.
(2011). Fyn, a potential target for Alzheimer’s disease. REVIEW. Journal of
Alzheimer’s Disease, 27(2): 243-252. *these authors contributed equally to this work
ABSTRACTS/POSTERS
Belrose, J.C., Johnson, M., Li, H., Jackson, M.F. MacDonald, J.F. Regulation of
TRPM2 function by glutathione and fyn kinase: Implications for neurotoxicity
following stroke. Poster presented at the Canadian Stroke Congress, Calgary, Alberta,
Canada (September 2012).
Belrose, J.C., Johnston, M., Chen, M., Li, H., Martyn, A.C, Prado, M.A., Prado, V.F.,
Jackson, M.F., MacDonald, J.F. TRPM2 is implicated in cellular senescence and Aβmediated toxicity in hippocampal neurons. Poster presented at the Canadian Association
for Neuroscience conference, Vancouver, British Columbia, Canada (May 2012)
Belrose, J.C., Caetano, F., Li, H., Chen, M., Jackson, M.F., MacDonald, J.F. (March
2012). TRPM2 is implicated in cellular senescence and Aβ-mediated cell death of
hippocampal neurons. Poster presented at the London Health Research Day, London,
Ontario.
Belrose, J.C., MacDonald, J.F., Jackson, M.F. (September 2011). Reduced glutathione
inhibits TRPM2 currents. Poster presented at the Canadian Society for Clinical
Investigation Young Investigator Forum, Ottawa, Ontario.
Belrose, J.C., MacDonald, J.F., Jackson, M. (July 2011). TRPM2 current potentiation
with age in vitro is dependent on oxidative stress. Poster presented at the 8th IBRO
World Congress of Neuroscience, Florence, Italy
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Caetano, F., Leon, N., Belrose, J.C., Jackson, M.F., MacDonald, J.F. (May 2011).
TRPM2 channel regulation by the Fyn kinase. Poster presented at the 31st Annual
Meeting of the Southern Ontario Neuroscience Association, Guelph, Ontario.
Belrose, J.C., Jackson, M., MacDonald, J.F. (March 2011). TRPM2 currents are
augmented by chronic oxidative stress. Poster presented at the 2011 Margaret Moffat
Research Day, London, Ontario.
Belrose, J.C., Masoudi, R., Fahnestock, M. (November 2010). Increased proNGF and
decreased BDNF in non-Alzheimer’s disease tauopathies. Poster presented at the
Society for Neuroscience, San Diego, California
Belrose, J.C., Jackson, M., & MacDonald, J. (September 2010). TRPM2 currents
increase with age in vitro. Poster presented at the Canadian Society for Clinical
Investigation Young Investigator Forum, Ottawa, Ontario.
Belrose, J.C., Jackson, M., & MacDonald, J. (March 2010). TRPM2 currents increase
with age in vitro, and may be functionally linked to NMDA Receptors. Poster presented
at Margaret Moffat Day, London, Ontario.
INVITED PRESENTATIONS
Belrose, J.C.*, Appleton, T.*, Ward, M., Young, F. (2011, September) Strength in
numbers: Growth of Canadian clinician investigator training. Paper presented at the
2011 Canadian Society of Clinical Investigation / Clinician Investigator Trainee
Conference, Ottawa, Ontario. *these authors contributed equally to this work
Belrose, J.C., Li, H., Jackson, M.F., MacDonald, J.F. (2010, November). A potential
role for TRPM2 in Alzheimer’s disease. Presented at the 2010 Anatomy and Cell
Biology Research Day, London, Ontario
TEACHING EXPERIENCE
Mentored 4th year Undergraduate Honors Thesis Projects
Toby Yip – 2009 - 2010
Nilien Leon – 2010-2011
Lynn Gierszewski – 2011-2012
Sept ’08 – April ‘09 Teaching Assistant – School of Nursing
 Courses: Health Science 1CC7/2CC7 – Integrated Biological Bases of
Nursing I & II
 Facilitated a tutorial of 15 RPN to BScN (diploma to degree) nursing students

178

VOLUNTEER HISTORY
2011 – present
MD/PhD student representative – University of Western Ontario
 Student representative at recruitment events, Schulich Grad Studies Student
Representative Council, MD/PhD committee, & MD/PhD admissions
committee
2011 – present
MD/PhD Program – Seminar Series
 Organize bi-monthly seminar series to increase mentorship between
established clinician scientists and current trainees at the University of
Western Ontario
2009 – 2012

Clinician Investigator Trainee Association of Canada (CITAC)
Positions:
VP External/VP External-elect (2010 – 2012)
Policy Director (2009-2010)
 Represent CITAC in forming partnerships with external groups & develop
memoranda of understandings with collaborating agencies
 Develop policies of interest to membership (i.e., funding advocacy for
trainees)
 Coordinate special interest projects

